annual report roche group annual report group account roche holding ltd basel annual account key figure millions chf figure report figure report financial statement adjust basisa change change sale ebitdab operating profit net income research development addition property plant equipment personnel number employee december ratio ebitda sale operate profit sale net income sale research development sale datum share nonvoting equity security chfc earning share nonvoting equity security dilute dividend share nonvoting equity securityd adjust figure internal management roche group represent result group underlie ongoing operation exclude special item include continue business seepage description reconciliation ebitda earning interest financial income tax depreciation amortisation include impairment correspond operate profit depreciation amortisation include impairment number share share information restate share split take place note financial statement dividend proposed board directorsgroup performance glance latot latot latot latot latot sale divisionin millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavours nonvoting equity security genussschein price performance chf roche nonvoting equity security adjust swiss market index rebase group figure net income millions chf net income share ebitda millions chf nonvoting equity security chf operating profit million chf research development millions chf addition property plant equipment million chf special charge figure adjust basis figure fully comparable previous year givaudan spinoff genentech transaction accounting policy change share information restate share split take place roche group annual report group account roche holding ltd basel annual account table content letter chairman board directors executive committee division pharmaceutical diagnostic vitamin fine chemical actionable health information people environment human resource safety environmental protection social involvement finance financial review consolidated financial statement note consolidated financial statement report group auditor multiyear overview hold finance company roche security roche holding ltd basel financial statement note financial statement appropriation available earning report statutory auditor roche global market presence operating subsidiary associate company table content day thousands dedicate roche employee con tribute skill talent innovation company success excellence healthcaregroup sale local currency swiss franc increase operate profit margin net income decline slightly result reduce financial income high tax expense strong cash flow solid balance sheet pharmaceutical division profitability improve pharmaceutical pipeline new molecular entity global leadership diagnostic reinforce diagnostic division margin strategic option vitamin fine chemical division review outlook good result adjust basisletter chairman overall successful year roche despite numerous challenge reflect particularly markedly improve operating result report core pharmaceutical diagnostic business year announce intention acquire majority interest japans chugai pharmaceutical alliance lead player world secondlarg pharmaceutical market negative past anti competitive practice vitamin industry repercussion comparable basis consolidate sale rise year local currency swiss franc billion swiss franc particularly letter chairmanpositive highlight increase adjusted operate profit billion swiss franc improvement group operate profit margin reach result expect decline financial income high tax expense adjust net income fall billion swiss franc roche record strong positive cash flow remains solidly finance include special item record report net income decline previous year billion swiss franc process renewal result number special way division equip itemsparticularly onetime gain future growthwe billion swiss franc sale evaluate strategic alternative genentech share vitamin fine chemical nonrecurre restructuring cost division outside roche focus additional provision record sharply core pharmaceu theconsolidate financial state tical diagnostic business ment yearonyear decline report net income good overall performance billion swiss franc possible great dedication pro roche report strong positive fessionalism employee display challenge yearand cash flow remain solidly finance like additional opportunity express apprecia tion contribu improve transparency tion comparability group current future performanceresult annual general meeting present actual basis shareholder board director adjust basis exclude propose dividend effect special item prac raise swiss franc tice adopt principle share nonvoting equity security follow compile adjusted genussscheinif approvedthis figure list group fifteenth dividend adjust basisnet income fall slightly increase year billion swiss francsa letter chairman provement group operate change introduce performance outweighed annual report infor decline financial income mativefor exampledisclosure high tax expensesthe group expand include profitability effective tax rate increase figure segment phar operating income account maceutical divisionand considerably high proportion find detailed information pretax income case compensation pay member previous year board director execu gain sale labcorp share tive committee payment tax united statesas group statutory resultpretax income rise auditorsto ensure group opera net income taxis tion manage supervise focus create value adjust operating profit rise board director establish billion swiss francsthank committee nonexecutive sale gain pharmaceutical member boardin diagnostic division signifi reinforce framework cantly improve cost structure corporate governance roche expenditure productionmarket create post compliance offi ing distributionand research cer ensure roche corporate development grow slowly principle adhere salesthis largely result groupthe new post finance risk manager establish meet requirement modern corpo group cost structure improve rate governance finance area significantly thank restructuring process pharmaceutical division pharmaceutical division record prescription drug sale billion swiss franc includ pharmaceutical division inggenentechthank measure restructure initiative reshape initiate divisionstagnant future growthlaunche sale growth quarter half implementation follow quarter initiative proceed swiftly market gainsresulte fullyear socially responsible manner sale increase local curren ciesthe global pharmaceutical expectednet financial income market grow year decrease yearfalle bil lion swiss francsthis primarily division achieve downturn world finan substantial ongoing cost saving cial market withits restructure programme operating profit margin apart improve comparabil sale prescription medicine ity financial statementsother rise percentage point letter chairmanebitda ofthe pharmaceuticals divi nations world health orga sion total billion swiss franc nizationwe currently conduct ofsalescompared number programme improve margin califor access antihiv medicines niabase subsidiary genentech fortovase viracept people report increase operating africa world develop profitfuelle strong sale growth nationshoweverfor roche year entire researchbase pharmaceutical genentech contribute positively industrypatent safeguard fair group operating result apply price remain absolutely vital high international accounting standard roche global market pharmaceutical division product annual sale leader important therapeutic area approximately billion swiss franc morethis represent significant oncology expansion revenue base recently rocephin level investment discovery product sale magni development new medicine tudein roche sustainedthanks global market leader important heavy commitmentfor exam therapeutic area oncologyour pleantihiv medicine belong company offer toa new class know fusion innovative new anticancer medicine inhibitor advance stage oncology franchise development andonce approve account approximately help counter grow prob fourth total prescription drug lem viral resistance toexiste sale hivtreatment growth topselle prod month uct offset loss generic focus research seven major competitor lower sale therapeutic area pursuit antihiv medicine result effective treatment increase competition price condition aidscancer reductionsdure year public alzheimer diseasediabete discussion pharmaceutical patent strokeour expenditure research pricing focus particularly development reach billion aid develop emerge swiss franc yearcounte market countriesin country optin right new compound howeverprevention programme roches pharmaceuticals pipeline andthe task build adequate comprise total new molecular medical infrastructure entitieswe currently pursue receive priority deserve development projectsinclud year roche actively e work supplementary indica involve fight aid tionsin expect receive work closely unite approval tamiflu european letter chairman union pegasys europe increase corporate consolidation united statesin additionwe customer competitor submit marketing application andeven importantthe year major new medicine possibility opportunity open sequence roche consumer healthour non human genome radically trans prescription medicine business form diagnostic industry increase sale local background change currencie billion swiss franc roche diagnostic create solid operate profit margin platform develop new business segment substantially modelstechnologie market report year alliance establish beforethis mark improvement lead company profitability result aggre accelerate strategic development sive focus key global brand roche diagnostic supplier clinically actionable healthcare diagnostic division expand information high share market reinforce position diagnostic likely global leader invitro diagnostic industry therapeutic sale rise local curren benefit scientific advance cie swiss franc ingenomic proteomicsroche billion swiss francsprofitability istherefore put substantial measure continue improve resource strengthen lead division operating profit molecular diagnosticsnotably ebitda margin advanced area pcr applicationsblood percentage pointsrespectivelyto screen cancer testing licensing dispute igen united statesa low court diagnostic area benefit issue decision require roche pay total million dollarswe breakthroughs genomic file appeal deci proteomic sionwhich regard unjustified excessivea previously report roche take lawsuit division business acquire boehringer mannheim area grow fast market record provision time contribute strong sale potential liabilitiesthe license agree performancethis balanced growth ment igen remain effect high baseline level unique final legal decision reach industry underscore roche diagnosticsnumberone position vitamin fine chemical globally key market division post sale billion united stateseurope asia swiss franc exclude medicinal feed additive business letter chairmandiveste divisional sale litigation resolve term rise local currency similar settlement inswiss francswhile vitamin reach individual civil suit great extentcarotenoid thedivision continue subject significant unbundling process begin pricing pressuresthese offset year ago create unit whichto byincreased volume sale alarge extentare legally organi vitamin rise sale revenue sationally independenta result number productsparticularly major condition place enzyme new product entry strategic realignment despite additional productivity divisionwe currently review gainsoperate profit ebitda possible option decrease million swiss franc million franc strong diagnostic respectivelythis decline pharmaceutical division work primarily low selling price make sense increase raw material medicalhealth economic com andenergy cost mercial term critical future successlast year open new division continue aggressively research building penzberg ger pursue measure improve symbolise important productivity profitabilityit aim crossdivisional element roche halve cost produce key strategyit combine modern research vitamin year development facility diag ensure longterm ability nostic therapeutic sin defend global market leadership gle roofour aim medium term draw new research dis year major strategic step take future shape strong diagnostic vitamin businesswith con clusion proceeding euro pharmaceutical division work pean unionfollowe early antitrust action united states make sense medical principal investigation health economic commercial term pricefixe practice date early vitamin industry critical future success bring closefurther progress madeparticu larly recent monthstoward coverie provide range treat resolve outstanding suit file ment closely tailor customersadditional provision need individual patientsinte million swiss franc grate healthcare solution tar record cover potential liability get medicine benefit arise customer lawsuit patientsthey help healthcare united statesthis base payer optimum use avail assumption outstanding able fund letter chairman expect proposed alliance sale growth stable operating japan researchbase chugai phar profit ebitda marginsover maceutical announce late thenext year expect important growth driver division operate profit margin alliance agreementchugai tomove japanese pharmaceutical subsidiarynippon rochewill merge anticipate year double roche acquire inter digit sale growth additional est new businessthe trans market share gain diagnos action significantly increase tic division division roche share japanese market operating profit margin increase second large pharmaceutical year market world beforeand year roughly novel business working raise slightly model japanese market well subject approval chugais share holder antitrust authority process ofrenewal countrieswe expect way division set stage transaction formally close successful futurethe givaudan end spinoffthe acquisition ofa majority interest chugaithe review bar extraordinary eventsthe begin ofstrategic option roche group anticipate overall vitamin fine chemical division sale growth current year andabove alltheimprovement mid high singledigit continually make operat rangewe expect small ing business allhave common goal improvement operating profit position roche innovative ebitda margin group strongly focus healthcare company levelgiven continue weakness deliver sustainable value financial marketswe anticipate patientsemployees shareholder mark decrease net finan cial income growth profitability pharmaceutical division depend largely extent accutane experience generic erosion go patent united stateshelpe strong product franz bhumer portfoliothe rollout new prod uct pegasys integra tion chugaiour pharmaceutical business position end year return mar ketlevel sale growth anticipate midsingledigit letter chairmanboard directors executive committee roche strengthen open annual general meeting elect walter frey serve remain transparent responsible management ing year retire member oversight group operation professor kurt jennys term board directorsjohn irving bell continue adhere principle nuffield professor clinical good corporate governance medicine university oxford elect boardhe succeed franz humer chairman board director professor charles weissmannthe annual general meeting vote toelect franz bhumer fouryear term board board director director annual general meeting april fritz gerber step board directorsthe executive chairman board committee employee director roche holding ltdin roche thank fritz gerber long recognition outstanding contri exceptional record service butionsthe board director wealso owe thank name fritz gerber honorary chair cantonal councillor kurt jenny man rochehe continue professor charles weissmannwho serve member board contribute greatly company directorsthe board elect chief growth executive officer franz bhumer successor board directors executive committeeboard director january leave walter frey john bell andre leuenberger andrea oeri franz humer andr hoffmann rolf hnggi henri meier fritz gerber peter brabeckletmathe year birth term end board director franz humer chairman andre leuenberger cid vicechairman rolf hnggi cid cid vicechairman fritz gerber honorary chairman peter brabeckletmathe cid andr hoffmann cid cid prof john bell cid henri meier andreas oeri cid walter frey cid secretary board directors gottlieb keller compliance officer franz humer stellt sich eine weitere amtsperiode al verwaltungsratsmitglie zur verfgung cid finance investment committee fritzgerber wird auf die generalversammlung al prsident zurcktreten der verwaltungsrat cid audit committee hat franz humer vorbehltlich wiederwahl durch die generalversammlung zum neuen cid remuneration committee verwaltungsratsprsidenten gewhlt fritz gerber gehrt nach seinem rcktritt al prsident weiter hin dem verwaltungsrat january kurt jenny tritt zurck und charles weissmann stellt sein amt auf die generalversammlung als verwaltungsrat zur verfgung walter frey und john bell werden der generalversammlung zur wahl den verwaltungsrat vorgeschlagen board directors executive committee current term ofvicechairman evaluation candidate rolf hnggi peter brabeck executive committee letmathe member board director end annual audit committee general meeting shareholder committee assist board theboard propose annual director oversee manage general meeting ment ofthe group businessespartic elect additional year ularly respect financial legal regular period office specify matter compliance internal article incorporationin business administrative policy additionthe american economist include policy safety envi deanne julius german politi ronmental protectionin execute cal scientist horst telschikchairman responsibilitiesthe committee quandt foundationwill review scope extent ofexternal nominate election board internal auditsthe independence objectivity ofthe auditor board committee theestablishment ofappropriate orga corporate governance roche nisational structure safety servesto ensure management environmental protection oversight group operation conduct responsibly finance investment committee focus create valuethe board finance investment committee director delegate certain mat assist board issue relate ter committee detail financeinvestment capital asset attention prior referral include evaluation risk boardthey presidium areasspecificallythe commit board director comprise tee review chairman vicechairman boardthe audit committeethe accounting system procedure finance investment committee organisation scope andthe remuneration committee financial control financial planningbudget auditfinance investment budget execution remuneration committee financial reporting shareholder compose board member general public member execu financial investment tive committee remuneration committee presidium board director application chairman chairman vicechairman remuneration committee serve jointly nomination com approve group compensation mitteein capacity prepare policy compensation receive proposal board director member executive com appointment new mitteegeneral manager major board member concern roche affiliate highlevel succession planning employeesin additionit approve board director executive committeeexecutive committee january row leave erich hunziker franz humer markus altwegg row leave william burns richard laube heino von prondzynski daniel villiger jonathan knowles year birth position executive committee franz humer chief executive officer erich hunziker chief financial officer control william burns pharmaceuticals division heino von prondzynski diagnostic division markus altwegg vitamin fine chemical division richard laube roche consumer health prof jonathan knowles global pharmaceutical research daniel villiger corporate service secretary pierre jaccoud executive committee statutory auditor ernst young ltd roche holding ltd group auditor pricewaterhousecoopers january board directors executive committee employee option programme million swiss franc service equity profitsharing renderedthey pay mil devices define general policy lion swiss franc additional audit oncompany pension benefit ing service million swiss franc postemployment benefit plans tax advice million swiss franc consulting service compensation member board statutory auditor ofroche director receive annual compensa hold ltd subsidiary tion swiss franc ernst young ltd receive serve onthe boardthe compensa swiss franc service render tion pay chairman deduct anda swiss franc hisagreed salarymember forother advisory servicesernst serve board committee receive young ltd act independent additional compensation auditor genentechincfrom swiss franc time receive million swiss franc expense genentechs security exchange commission audit additional member executive compensation million swiss committee receive fix salary franc separate service total swiss franc variable bonus total compliance officer swiss franc total early board director stock option price swiss roche holding ltd vote create franc position compliance officer thecompliance officer responsible optionswhich maynot exer ensure roche corporate cise yearsentitle holder principle consistently adhere topurchase roche nonvoting equity grouphe security genussscheineat ratio contact person shareholder price swiss franc employeescustomerssupplier eachthe option trade general public issue relate stock exchange exercise group corporate principle april december good corporate governancein value swiss create positionthe board franc eachthe option director underscore impor underlie nonvoting equity securi tance attaches high standard tie hold reserve buy area integrity roche thestock market programme board director appoint result inadilution gottlieb keller compliance officer value roche securities gottlieb kellerwho hold post continue serve secretary relationship group auditor board directorsreport andstatutory auditor directly tothe chairman board group auditorspricewaterhouse regular report coopers receive compensation board audit committee board director executive committeeexecutive committee effective october board director appoint erich hun ziker executive committee roche new chief financial officer succeed anton affentrangerwho leave roche mayerich hunziker yearold swiss national hold phd industrial engineering federal institute technol ogy zurichfrom erich hunziker hold lead position finance areathe diagnostic pharmaceutical busi ness boehringer mannheim chief financial officer corangebefore join rochehe serve chief executive officer diethelm kelleran international trading group base zurich companys article incorporation find wwwrochecom board directors executive committee heart transplant save marcel life roche cellcept making sure body reject new heart continue volunteer work swiss heart lung trans plant association les cur ace heart roche establish foundation support research transplantation medicine roche organ transplan tation research foundation currently support large number study university transplant centre research institutespharmaceutical division brief million chf change sale prescription otc ebitda operating profit expenditure employee include genentech adjust basis pharmaceutical difficult start month sale prescription medicine grow fast global market quarter growth fuel primarily extremely successful oncology franchise number lead product compensate lose sale result expiry patent verseddormicuman important milestone reach launch pegasys hepatitis market restructure programmereshape future growth accelerate growth prescription drug sale reduce cost year positive impact profitability pharmaceutical business december roche chugai announce alliance create lead researchdriven pharmaceutical company japan roche hold majority interest company rank fifth sale world second large pharmaceutical market pharmaceutical profit margin ofafter margin division ebitda total million swiss francsor ofsalesand percentage point high year beforethis improvement profitability areflection ofhow successful ourreshaping future growthinitiative beenit achieve despite aonetime gain million swiss franc record thesale ofthe north american right coreg prescription pharmaceutical strong growth oncologytotal pre scription drug sale include genen tech increase million swiss francsfor yearonyear growth rate local currency swiss francson adjust basis operate profit prescription restructure initiative business reach million swiss francsthis equivalent reshape division future growth ofsalescompare improve division performance ebitda total million swiss francsor ofsalescompare term sale profitability margin roche oncology power exclude genentechprescription house successfully introduce drug sale rise million swissfrancsfor growth rate innovative hepatitis medicine pegasys local currency swiss franc adjust basisoperating profit market total million swiss francsthe william burns head pharmaceutical division operate profit margin margin previous year ebitda reach million swiss pharmaceutical sale franc andwa equivalent profitability increasedsale salescompare pharmaceutical division rise local currency swiss franc genentech sale improve million swiss franc million swiss franc adjust basisoperating profit local currency swiss reach million swiss franc francsoperating profit total equivalent operating million swiss francsthis equiva pharmaceuticalslent ofsalesup nega total divisional sale million chf tive operating profit margin turnaround resultofstrong sale growth come despite high cost incur increase salesebitda increase million swiss franc andwa ofsale slightly prior year level prescription sale growth roche andgenentech lead ouroncology portfoliowhich account ofour prescription drug businesslast year roche fast marketthank primar becamethe global market leader ily successful launch ofour key therapeutic areamoreover important cancer medicine roche company bycontrastsale europe show new oncology product herceptin midsingledigit growthin latin xeloda mabtherarituxan america sales contract roughly whichhave show clinical rate market trial improve patient survival owe price reduction antihiv major growth driver include medicinesand macroeconomic prob cellceptwhich transplan lem regionsale advanced tation medicineand anemia treat bydoubledigit percentage ment neorecormonthe antibiotic regionsfuelle primarily rocephin xenicalour lead launch ofxenical major asian weight loss medicationalso post market growth oncology roche move growth product lead portfolio innovative offset loss expiry medicine canceroncology ofour verseddormicum patent ofthe therapeutic area theunite statesthe delisting currently inno draganon japan price reduc vativeit area tion antihiv productswhich strong growthtotal sale ofour weresubject increase competitive cancer medicine increase pressure price erosion million swiss franc theyear make roche world lead sup plier key therapeutic areathe sale ofprescription medicine innovative biotechnology product north america show doubledigit herceptin andmabtherarituxan gain ofthank strong sale ledthis strong performancewith growth genentechin japanthe majorcontribution come world second large pharmaceutical xelodaa novel tumourselective marketsale grow time treatment pharmaceutical sale ofmabtherarituxanthe primarily launch western humanise monoclonal antibody europe japan brisk sale treatment ofcanceronce inthe united statesthis monoclonal doubledrise million swiss antibody show signifi francsin drug approve cantly increase survival breast japan use indolent non cer patient overexpress hodgkin lymphoma nhlnhl agene associate aggressive frequent form ofblood cer cell growth cermabtherarituxan show improve survival xeloda sale rise sharplyadvanc patient aggressive nhla fast ing local currency mil grow form ofthe cancer affect lion swiss francsthis oral anticancer halfofall nhl patient agent activate inside cancer cell inoctober european committee deliver effective chemotherapy proprietary medicinal product cancer cell spare healthy one prescription product include genentech metabolic japan disorder latin america dermatology central nervous system oncology sale region sale therapeutic area infectious disease virology north america europe cardiovascular disease inflammatory autoimmune disease cpmp issue positive opinion xeloda approve use ofmabtherarituxan market metastatic breast new indicationadditionallythe drug colorectal cancer potential investigate potential use type ofcancer inautoimmune diseasesmabthera approval colorectal rituxan undergo phase cancer receive february clinical testing combination mayrespectivelyxeloda recently chemotherapy agent fludara approve united states berlexinitial positive result usein metastatic breast cancer obtain patient taxotere aventisthe cpmpha previously untreated chronic lympho recommend european approval cytic leukemia ofxeloda singleagent ther apy combination taxotere sale ofherceptin grow combined chemotherapy signifi local currency million swiss cantly improve survival inmetastatic francsthis sharp increase drive breast cancer pharmaceuticalstarceva promise new anticancer agent develop roche genentech partnership osi pharmaceuticalspreparation phase iii clinical testing nonsmall cell lung cancer begin additional phase phase iii trial currently way indicationsthis novel oncol ogy product potential effective range ofdifficulttotreat cancerssuch lungovarianbreast colorectal cancer supportive carekytrila bondronat thirdgeneration bis potent antiemetic control phosphonate management nausea vomit patient hypercalcemia abnormally elevate undergo cancer chemotherapy serum calcium cause cancer post sale million swiss afile europe use metastatic franc year bone disease breast cancer patient acquire rochein united planned states marketing application file year use ofkytril transplantation continue strong inpostoperative nausea growthroche strongly commit vomit improve longterm outcome oftransplantation enhance sale ofthe recombinant growth factor quality oflife oftransplant recipient neorecormonwhich stimulate group transplantation portfolio production ofre blood cellsrose generate total sale million local currency reach swiss franc increase million swiss francsalthough year anemia associate poor kidney function main sale driver cellcept establish itselfas considerable growth come cornerstone ofeffective longterm use ofthe drug hematological immunosuppressive therapy prevent cancersan indication approve rejection oforgan transplantssale europe yearthe establish substantially year role ofneorecormon nephrology rise local currency strengthen european million swiss francsthe potency approval ofa newonceweekly dose cellcept make possible reduce schedulethe product currently use ofmore toxic immunosuppre inclinical trial todetermine sive drugsunlike product suitable supportive cancer cellcept toxic kidney therapy patient solid tumour increase risk ofcar improvedsecondgeneration diovascular disease benefit product development result long transplant patient pharmaceutical survivalcellcept approve francslaunche inmajor asian mar europe year use child ket helped grow salesa follow kidney transplantation focus marketing strategy put great emphasis patient support zenapaxwhich combina satisfaction contribute tion cellcept prevent acute stabilise sale united states kidney transplant rejectionposte increase sale achieve sig sale million swiss francssale nificantly low costxenical ofcymevenecytovenean antiviral available weight loss medication work locally gastrointesti nal tractwhere reduce absorp tion ofdietary fat additionoverweight type diabetic treat xenical clinical trial find lose significantly weight treat diet aloneapproximately ofpeople type diabete overweight excess weight impor tant modifiable risk factor develop ment ofthiscondition virology major innovationsin roche important virology port agent hiv care folio strengthen transplantation treat prevent approval ofpegasys hepatitis eyeinfection cause cytomegalo marketsswitzerlandmexico virus cmv retinitis include sale venezuelathis newgeneration ofit oral formulation valcytegrew pegylate interferon potent medi valcyte launch cationprovide sustained virus sup united states treat cmv pression dose week retinitis hiv patientseuropean clinical trial show restofworld approval number ofpeople virusfree expect quarter month treatment stop onwork way high pegasy amarkete application use singleagent therapymoreover transplantationwhich expect combined therapy pegasy submit later year ribavirin show clearly effective regimen xenical lead medicine compromise tolerability weight loss weight control approval single xenical world lead prescrip agent combination therapy tion product treatment ribavirin include roche obese overweight patientssale ribavirin expect mid ofxenical rise moderate europe end local currency million swiss ofyear united states pharmaceuticalsmajor product approval launch product generic indication country roaccutane accutane isotretinoin severe acne pediatric exclusivity usa cellcept mycophenolate mofetil prevention acute rejection pediatric kidney transplantation herceptin trastuzumab metastatic breast cancer japan mabtherarituxan rituximab indolent nonhodgkin lymphoma japan neorecormon epoetin beta weekly anemia chronic renal failure anemia patient hematological malignancy pegasys pegylate interferon alfaa hepatitis switzerland mexico venezuela tamiflu oseltamivir treatment influenza japan valcyte valganciclovir cytomegalovirus infection immunocompromise patient usa xeloda capecitabine metastatic colorectal cancer usa xeloda taxotere capecitabine docetaxel metastatic breast cancer usa include supplemental indication update midfebruary patent extension february base pediatric data sale oftamiflu increase local class ofmedicine currencie million swiss franc mainstay ofmany antihiv despite modest sale treatment regimenssale decline canbe attribute year year local currency mild flu seasonthe product estab mount competitive pressure lishe itselfas market leader newly launch antihiv medicine tamiflu successfully launch price reduction provide japan early marketing develop country improve access application file important drug account pediatric formulationapproval drop sale revenuesale europe treatment pre proteaseinhibitor expect vention ofinfluenza adult stabilise volume growth adolescent child expect partially offset continue low price viraceptfortovase invirasethe trimerisroche protease inhibitor core develop tthe ofa new hiv portfoliogenerate com class ofmedicine know fusion bin sale million swiss franc inhibitorsunlike exist hivaid pharmaceutical topselle prescription product include genentech change sale change local product generic indication millions chf chf currency rocephin ceftriaxone bacterial infection mabtherarituxan rituximab nonhodgkin lymphoma roaccutaneaccutane isotretinoin severe acne cellcept mycophenolate mofetil transplantation xenical orlistat weight loss weight management herceptin trastuzumab metastatic breast cancer neorecormon epoetin beta anemia viracept nelfinavir mesylate hiv infection kytril granisetron chemotherapy radiation therapyinduce nausea vomit nutropin protropin somatropin somatrem growth hormone activase tnkase alteplase tenecteplase myocardial infarction pulmozyme dornase alfa dnase cystic fibrosis neupogen filgrastim gcsf neutropenia furtulon doxifluridine cancer colon breast stomach cymevenecytovene ganciclovir cytomegalovirus infection valcyte valganciclovir dilatrend carvedilol heart failure hypertension angina pectoris lexotan bromazepam anxiety tension state xeloda capecitabine colorectal breast cancer madopar levodopa benserazide parkinson disease rocaltrol calcitriol osteoporosis inhibace inhibace plus cilazapril hypertension torem torasemide hypertension roferona interferon alfaa hepatitis cancer invirase fortovase saquinavir hiv infection rivotril clonazepam epilepsy dormicumverse midazolam anesthesia sedation jointly market roche genentech product post sale billion swissfranc half division tenproduct show doubledigit sale growth sale anticancer drug mabtherarituxan double make roche second well sell pharmaceutical antibiotic rocephin pharmaceuticalsdrugswhich work inside host cell product sale target viral enzyme involve decline local currency hiv replicationt inhibit million swiss franc fusion ofhiv host cellsthu dual pressure ofgeneric competition block virus enter cell number ofmarket begin replicatet restrictive prescribing environment expect offer new therapeutic united statesthe product option pretreate patient face challenge generic hivincluding infect united states patent expire drugresistant strain ofthe virus spring approximately patient previ anticipate downturn salesit ously treat antihiv magnitude depend ability medication currently participat ofgeneric manufacturer replicate ing phase iii trial evaluate stringent safety programme novel medicineifthe clinical trial placein close cooperation result positive expectedand food drug administra sophisticated production facility tion fdato ensure safety require manufacture complex patient undergo treatment peptide complete schedule accutaneroaccutane regulatory filing sub mitte united states europe dilatrendan agent prove second halfof entire spectrum ofheart failure condi tion far effective con establish product newcom ventional betablockersachieve dou er high potentialrocephin bledigit growthwith sale totalling lead antibioticremain million swiss francsgrowth drug ofchoice treat bacterial fuel publication oftwo infection hospitalssale ofthe landmark trial investigate drug product year insevere chronic heart failure post advance local currency myocardial infarction patientsdata million swiss francsthank show dilatrend confer highly oncedaily convenience contin significant survival benefitin addition ued effectiveness broad range substantially reduce hospitalisa ofpathogensrocephin sale grow tion improve patientsquality despite generic competition num liferoche pursue supplemental ber ofmarketsrocephin remain approval ofthe drug use patient akey contributor roche prescrip severe chronic heart failure tion drug sale strong sale united states bonviva highly effective bisphos product offpatent phonate develop treat italy compensate generic erosion ment prevention ofosteoporosis great market potential score late announce roaccutaneaccutanethe effec ment roche glaxosmithkline tive treatment available severe agree codevelop copro acneremaine ofour bestselle mote productlatestage clinical pharmaceutical test ofthe drug operate profit marginwhich complete show bestinclass climb adjust basis reduction risk ofvertebral frac singledigit figure turesbonviva bisphospho year increase nate prove ability reduce adjusted operating profit reach fracture risk ifpatient million swiss francsfor increase week drug holiday quarter ofebitda adjust grow initial regulatory filing europe million swiss francs united states plan equivalent ofsale compare sale continue grow ahead ofthe otc marketwhich stagnant overallsale show modest gain local currency slightlydecline swiss franc term slip million franc exclude market experience significant macroeconomic difficulty year argentinabrazil turkeyresulte drop salesrch post sale growth local currenciesthis increase come despite elimination ofthe resale price roche consumer health focus brand maintenance system united kingdoma change adversely clear benefit consumer impact result europe future growth work sale vitamin segment decline exciting new business model area local currenciesroughly line age weight management market trend segment core redoxon supradyn richard laube head roche consumer health brand hit particularly hard economic downturn country market roche consumer health leadersand low incidence roche consumer health rch offluand cold tenth year ofoperation see con ofeurope negative impact tinue progress create strong onsale brandsover year rch key global brand average annual significant progress growth today account analgesic segmentmore offset nearly ofour nonprescription te low sale ofvitamin product otc salesby focus aggressively continue sale growth aleve profitable growthsince itsfound especially united statesfurther ing rch significantly improve market expansion europe pharmaceuticalssuccessful rxtootc switch consumer selfmedication naproxenbase brand latin america contribute success highlight continued skin hair care sale growth ofour bepanthen skin analgesic gastrointestinal product care brandfollowe successful relaunch europethe brand sale therapeutic area cold remedy expand market vitamin research development highly promising pipelinethe signif icant investment pharmaceutical division create groupwide process move proj focus global otc brand ect seamlessly research devel change sale change local opment marketing start product use millions chf chf currency tobear fruitthank increase pro aleve naproxen analgesic ductivitythe division supradyn multivitamin pipeline ofimportant new medicine bepanthen skin care highly promising term rennie antacid ofboth quantity quality redoxon vitamin ofproject berocca multivitamin saridon analgesic division pursue total elevit pronatal multivitamin research project seven key therapeutic areasoncologymetabolic disordersinflammatory disease genitourinary diseasescentral nervous total ofover project pur system disordersvascular disease suedinclude supplemental indica virologyin ofthese area tionseleven nme earlystage significant unmet medical need phase developmentsix commercial potential enter phase clinical testingeight product address need phase iiand phase iii correspondingly highwith new pharmaceutical pipeline molecular entity nme reach strengthen optin right addi preclinical development tional nme agreement roche leader pharmaceutical genentech basilea pharmaceutica research productivityseveral ofthese potential new medicine project enter phase clinical genentech commercialise testing partiesinclude rocheexpect additional nme theseadditional compoundsthere enter preclinical development nme roche pipeline currently nme moreoveronce transaction division development pipelineand chugai closedroche pharmaceutical right license project research project major therapeutic area chugai seek partner outside japan south koreachugais focus oncology bonerenal cardiovascular diseasesand metabolic disease expect toyield number ofcom virology oncology vascular disease pound suit global development marketing genitourinary disease inflammatory disease successful research unit central nervous system kamakura japan merged chugais research organisation strengthen japanese company innovative capability gene drug discovery collabo ration decode genetic produce breakthrough finding yearnew target identify analyse gene link common disease schizophrenia periph eral arterial occlusive disease basis drug diagnostic discovery programmea gene contribute stroke identifiedand researcher decode map chromosomal loca new knowledge molecular tion ofgene link type dia betesobesity clinical anxietythe pathology human disease mapping ofthe gene link open new opportunity create torheumatoid arthritis provide genetic marker predict novel medicine diagnostic scientist increase risk ofdevelope dis roche taking lead new easeall achievement mark important early step turn global multidisciplinary approach discoverie genomic dramatic improvement healthcare turn datum specific knowledge allow invent important ofeffort streamline research organisationthe pharmaceu new medicine future tical division discontinue research activity welwyn united jonathan knowles head global pharmaceutical research kingdomwelwyn viral disease research unit transfer palo alto unite statesstrengthene highly productive sitewhich pharmaceuticalsfile solid pipeline indication therapeutic area projectproduct type generic major line extension phase phase phase phase iii phase anemia generation anemia treatment renal anemia cancerrelate anemia neorecormon glycoprotein epoetin beta needlefree injection system radiotherapy anemia prematurity weekly oncology inflammationbone nuclear receptor modulator osteoporosis kinase inhibitor rheumatoid arthritis rbonviva bisphosphonate ibandronate treatment osteoporosis mabthera monoclonal antibody rituximab rheumatoid arthritis metabolism nuclear receptor modulator type diabetes gpcr modulator obesity enzyme activator diabetes insulin sensitizer type diabetes xenical lipase inhibitor orlistat development japanc pediatric indication prevention diabete treatment diabete nervous system gpcr modulator depression gpcr modulator depression anxiety gpcr modulator depression anxiety oncology enzyme inhibitor solid tumour gpcr modulator emesis kinase inhibitor solid tumour monoclonal antibody solid tumour cell cycle inhibitor solid tumours rtarceva kinase inhibitor solid tumour pegylate recombinant protein gcsf pegylate filgrastim chemotherapyinduce neutropenia rpegasy pegylate interferon peginterferon alfaa malignant melanoma bondronat eubonviva bisphosphonate ibandronate metastatic bone disease breast cancer herceptin monoclonal antibody trastuzumab joint development activitiesc rochesponsore activitiesc mabthera monoclonal antibody rituximab aggressive nonhodgkin lymphoma xeloda capecitabine firstline combination metastatic breast colorectal cancer adjuvant monotherapy combination colon rectal breast cancer respiratory integrin antagonist asthma integrin antagonist asthma nuclear receptor emphysema nuclear receptor emphysema transplant valcyte nucleoside analogue valganciclovir prevention cytomegalovirus infection solid organ transplantation cellcept impdh inhibitor mycophenolate mofetil acute renal transplant rejection urology gpcr antagonist benign prostatic hyperplasia gpcr antagonist overactive bladder pelvic hypersensitivity gpcr antagonist stress urinary incontinencevirology protease inhibitor hiv infection rlevovirin new generation nucleoside analogue hepatitis fusion inhibitor hiv infection fusion inhibitor hiv infection rpegasy pegylate interferon peginterferon alfaa chronic hepatitis pegasys pegylate interferon peginterferon alfaa hepatitis pegasys ribavirin peginterferon alfaa ribavirin chronic hepatitis roche ribavirin pegasys ribavirin peginterferon alfaa roferona interferon alfaa chronic hepatitis valcyte nucleoside analogue valganciclovir treatment cytomegalovirus retinitis patient aid fortovase protease inhibitor saquinavir pediatric formulation tamiflu neuraminidase inhibitor oseltamivir treatment prevention influenza viracept protease inhibitor nelfinavir mesylate hiv infection new formulation optin opportunitiesa basilea pharmaceutica bal antifungal fungal infection bal antifungal fungal infection bal antibiotic bacterial infection bal nuclear receptor plaque psoriasis bal cisretinoic acid chronic hand eczema pozen gpcr modulator migraine speedel endothelin receptor antagonist cardiovascular disease genentech trastuzumabdm antibody solid tumour antitissue factor monoclonal antibody fragment acute coronary syndrome amd fab monoclonal antibody fragment agerelate macular degeneration ldp antibody monoclonal antibody inflammatory bowel disease avastin antivegf antibody avastin solid tumour chemotherapy participation genentechb antiige antibody allergic asthma allergic rhinitis thrombopoietin protein thrombocytopenia xanelim anticda antibody psoriasis xolair antiige antibody allergic asthma anticda antibody anticda antibody solid organ transplant rejection external partner genentechosi phase trial currently preparation pharmaceutical division currently nme development pipeline earlystage shearwater amgen phase trial currently preparation development phase enter phase clinical testing phase phase iii genetics institute icn roche retain right license product total project pursue include supplemental indication nmes genentechidec trimeris consolidation roche pipeline vernalis gilead competitive reason project genentech agouron identify phase transition preclinical clinical development phase initial study healthy volunteer phase smallscale efficacy tolerability dosefinde study patient bluetype represent new molecular entity nme phase iii largescale study patient statistical confirmation safety efficacy current january phase datum longterm efficacy effect follow marketing approvalfocuse discovery early add impetus growth clinical development ofnew medicine expect come merger inflammationrespiratory disease nippon roche chugaiannounced bone disordersneurobiological disor late mergerwhich der genitourinary diseasesthis create novel business model step underscore roche commitment japanese marketis subject maintain strong presence approval bychugais shareholder area ofhivaids hepatitis antitrust authority countriesthe necessary approval outlookthe pharmaceutical division anticipate fourth quarter currently expects midsingle digit sale growth signifi extentsale performance help strong product portfolio beinfluence soon accutane rollout ofnew product roaccutane face generic competition integration ofchugaiour pharmaceu marketthe division tical business position focus particular driving end ofthis year return oncology franchisewhile strengthen marketlevel sale growth ing position therapeutic objectivewhich expect achieve area wellwe anticipate continue yearsis increase doubledigit sale growth operate profit margin lead anticancer drugsnotably pharmaceutical division herceptinmabtherarituxan present level xelodathese medicine neorecormon currently investigate useinnew indication approval ofmabtherarituxan aggressive nhl double poten tial patient population eligible treatment medicinewe look growth lead roche productssuch cellceptdilatrend xenicalwe anticipate approvals tami flu european union pegasys europe united statesmarketing application bonviva united states europefor bondronat europe pegasy japan important filing plan additionallyapproval anticipate number ofimportant line exten sion new indication exist product pphhaarrmmaacceeuuttiiccaallss clinical practice get right diagnosis quickly decisive roche lightcycler prof laboratory perform variety genetic test deliver diagnostic information fast help doctor right treatment decision roche supply innovative system technology genomic proteomic research main focus develop new application pcrbase diagnosticsdiagnostic division brief million chf change sale diabetes care near patient testing centralized diagnostic molecular diagnostic apply science ebitda operating profit expenditure employee diagnostic roche diagnostic post doubledigit growth rate market averagea result division expand lead market segment national market serve rollout new product customer range highworkload laboratory individual consumer positive impact sale division operate profit margin show yearonyear gain position strength roche year implement major initiative point way forward new dimension medical diagnosticswith business area focus tightly customer roche diagnostic responsive market need alliance iceland decode genetic develop new genebased diagnostic system mark important step roche road individualised healthcare diagnostic profitability measure continue improveoperate profit increase million swiss francswhile ebitda advance million swiss francsthe division operate profit margin rise percentage point ebitdamargin percentage point strong sale growth offset increase cost incur yearparticularly market distributiona new strategic alliance license apart expertise high growth area molecular diag nostic dataassiste patient self managementa number attractive new product contribute year solid performancethese include accuchek compact sys tem blood glucose selfmonitore consumer diagnostic segment challenge face continue modulewhich add immunoassay capability cost grow fast marketa market savinghighthroughput modular leader roche diagnostic shape analytic system largevolume laboratory market way build strength focus business diagnostic division file anappeal court judgement sharply customersneed award igen international million dollar compensatory dam heino von prondzynski head diagnostic division age million dollar puni tive damage inlitigation bring igen united statesthe litiga increase sale profitability tion concern claim relate sale local licensing igen electrochemilumi currenciesroche diagnostic nescence ecl technology roche outpace market substantial diagnostic marginsale advanced mil lion swiss francsreinforcing divi strong sale growth region sion position world leader sale double invitro diagnosticsroche hold digit percentage grow signifi share global market cantly fast market diagnosticsfive geographic region total divisional sale million chf division businessthe large increase come japanwhere sale advance north america gain report strategi cally important product line market segmentsineurope bse test market division particularly strong growth driver increase sale iberialatin america primarily division strong service offering highperformance solution aim serve need laboratoriessale genebase test health professional link account formuch robust new lab network growth japanthe establishment organisationthese business roche diagnostic shanghaiopene area complement apply direct access highgrowth sciencewhich supply university chinese marketwa key factor industry reagent sys healthy sale increase tem research project report asiapacific region serve division breeding ground new technologiesand uncompromise customer focus diabetes carewhich focus exclu new role medicinethe diagnos sively diabete market tic industry midst tran sitiona customer competitor establish supplier lead strive grow business instrumentsreagent service merger acquisition roche diagnostic increasingly knowledge continue grow pioneer provide exponentially follow mapping sophisticated solution support human genomeitand ecom themthe main focus diagnostic mercewhich steadily gain information management tool importance diagnosticsare assist therapeutic decisionmake force change realtime link interpret new store patient diagnostic division datum respond challenge comprehensive strategic realignment number partnership create solid platform alliance help division forthe development new business implement strategic visiona modelstechnologie market license agreement chiron open opportunity division division centralize diagnos enhance strong interna ticsmolecular diagnostic near tional presence blood plasma patient testing business screen supplier diagnostic pcrbase product blood networkable accuchek bank marketthe alliance inform system hospitalsroche digene broaden portfolio diagnostic lead supplier test sexually transmit dis professional diabete monitoring ease oncologyan agreement system world large market innogenetic offer opportuni tie roche establish presence diabete care work diagnostic microbiology generation ofaccuchek pcrbase testsand cooperation compacta totally new type decode enable tap devicecombine digital organiser thetremendous potential genetic blood glucose meteris near genomic e launchthe device feature japan near patient testing apply science asiapacific europe molecular diagnostic sale region sale business area north america diabetes care centralize diagnostic iberialatin america business area growth track infrared datum port make easy diabete care roche dia patient comprehensive bete care log reading download division successful business datum system areaswith sale local currency research diabetes care go far develop everbetter glucose sale ofaccuchek advantagethe metersfor examplewe search world topselle blood glucose way measure blood glucose meter patient selfmonitore blood sam autumn pleone result effort major new product accuchek dtectorwhich diag launch north americaaccuchek nose type diabete bymeasure compactwhich feature integrate change eyesa largescale test strip automatic code clinical trial deviceis cur pret check strip integrityand rently wayour researcher accuchek activewhich perform arealso investigate continuous measurement second monitor technique tiny blood samplethe market employ artificial pancrea response product measure blood glucose level goodwe expand deliver insulin dose lead market launch bodywhen need diagnosticsto augment research activity roche diagnostic leader uri diabetesroche acquire califor nalysis multiparameter system niabased amira medical november give solid presence grow company knowhow ing primary care segmentresearch patent portfolio greatly facilitate development segment roche diagnosticsaccess fast aim develop newgeneration grow integrate spot monitor instrument substantially segment diabetes market small powerful data management capability near patient testingsale roche currently available near patient testing supplier product service doctor roche near patient testing officesambulance intensive care lead supplier coagulation unit year local monitor patient usewith currenciesmake divi coaguchek system pave sion fast grow business area way duplicate tremendous help successful integration success roche accuchek dia medical instrument business bete product coagulation acquire austria avl monitoring segment groupwe accelerate market share growth hospital pointof care segment rapid diagnostic prod uct emergency roomsintensive care unit hospital set tingsroche diagnostic consoli date lead position seg ment rollout omni blood gas analyser fourth quar ter omni opti plus additional system blood gas electrolyte measurementare expect reach market mid future hospital pointofcare centralize diagnosticsroche cen testing lie link testing tralize diagnostic leader device electronically hospital integrate analytical system hos laboratoriescentral datum man pital highvolume service labo agement systemsaccordinglywe ratoriesit main area concentra focus research activity tion system network develop innovative solution process optimisationsale rise like datacare linewhich allow year local currenciesa solid complex test datum manage result business area fiercely exchange ease competitive market diagnostic centralize diagnosticselecsys license agreement igen immunodiagnostic system achieve remain place final judge increase salesa significant ment reachedthe division growth driver module continue develop new test make possible elecsys systemsand con form highthroughput immunochem tinue market instrument test ical testingdevelope record cover licensing agreement include system broad pipeline diagnostic industry research effort centralize diag nostic focus tradi tional core areasas roche crossdivisional proteomic initiative diabetes care search new marker apply science early detection near patient testing monitor type major innovation expect business area year cancer metabolic inflamma tory diseasesin additionan agree centralized diagnostic molecular diagnostic ment sign january mil lennium collaborate develop marker rheumatoid arthritis time monthsthe module cover broad spectrum molecular diagnosticssale diagnostic applicationsin addition roche molecular diagnostic elecsy blood test prostate increase local currency cancer receive regulatory underscoring strength field approval launch genetic testinggrowth fuel diagnostic marker early detec primarily demand pcrbase tion heart failure impor product servicespcr poly tant addition roche diagnostic merase chain reaction molecular product portfolio cardiovascular biology technique capable produc disease ing million copy specific dna sequence short timethus hematology centralize diagno make possible diagnose dis tic post abovemarket growth ease quickly reliablypcr help alliance japan base test transmissible disease base sysmexthe new fungal infectionsparticularly hematology analyserlaunched test hepatitis hivaids receive market account substantial portion placecentralize diagnostic suc sale cessfully defend share blood coagulation monitor july molecular diagnostic automate urinalysis segmentscar receive regulatory clearance diac control ddimeratest qualitative pcrbase test myocardial damagehas nowalso hepatitis cfollowing expedite launch united states review food drug admin diagnosticsistration fdawith new case hepatitis report yearthere great market need highly sensitive test detect viral diseasewhich asymp tomatic early stage cobas ampliprepa system fully automates multistep process prepare specimen pcr analy siswas introduce number european country mayaddi tional market launch plan early roche enter alliance year analysissurpasse expectation partner healthcare system demand university decode geneticscombimatrix industrial researcher particularly quest diagnostic develop new genetic genebase diagnostic approach molecular testing remain strongroche con highly promising field phar tinually expand range test macogenomicspredictive medicine perform sys genomic tema recent example rapid anthrax test jointly develop apply scienceapplied science short timeframe mayo show impressive growthwith clinic united states roche sale increase local curren give result ciessale industrial biochemical hourtest dangerous supply amount rang pathogen currently devel ing kilogram tonnescon opedthe lightcycl comple tinue grow ahead mar mente module fully auto ketreflecting increase use mate nucleic acid extraction biotechnology industrial applica sample material tion agreement sign january rt world commercial swissbase prionic give roche cellfree protein expression system diagnostic global marketing receive market right prionicschecka highly rt roche diagnostic sensitive test bsea new version add innovative release october suitable use technology support research automate systemsenabling gene functionsan improve version simultaneous testing large number release december sample event massive outbreak sale lightcyclera system amplify genetic material dna diagnostic researcher patient widest range diagnostic product market research market healthcare provider enduser research lab service laboratory patients university hospital hospital consumer doctor office gps apply science molecular diagnostic centralize diagnostic near patient testing diabetes care roche diagnostic company division centralize diagnostic supply market segment researcher molecular diagnostic near patient consumer knowledge gain research testingbusinesse aim market flow directly create improve atserving need health professional innovative new product segment link new lab network mean short development times reduce organisation risk low cost substantial com petitive edge new test underscore roche raiseit operate profit margin diagnosticscustomer focuscapacity slightly well innovation ability react quickly new challenge enormous potential genomics proteomic significantly division expect dna chip tech accelerate growth entire health nology important care sectorwith diagnostic growth driverthe product industry likely reap expect end benefit breakthrough translate new outlookroche diagnostic con therapiesroche put tinue exploit opportunity substantial resource strengthen init push maintain doubledigit ing lead molecular diagnostic growth andin medium term especially pcr applicationsblood diagnosticsscreene cancer testingthe cer diagnostic market particular set undergo rapid expansion near futureroche diagnostic establish special unit integrated cancer care unitwith task pioneer commercially successful new test yearsthe division new structure strategic realignment basis roche intend consolidate global lead ership diagnostic market establish lead supplier clinically actionable healthcare infor mation diagnostic protection sun important small dose ultra violet radiation damage skin parsol slx novel uvb sunscreen roche supply cosmetic industry use sun cream increasingly cosmetic product everyday use roche active search new dis ease prevention strategy expertise molecular genetic roche work dis cover cause specific disease develop innovative product early disease preventionvitamin fine chemical division brief million chf change sale vitamin carotenoid fine chemical ebitda operate profit rdexpenditure employee adjust basis vitamin fine chemical vitamin fine chemical division world lead supplier healthpromote active ingredient feed food pharmaceutical cosmetic industrieshoweverthe division performance closely link customer industry currently experience slowdown market vitamin great extent carotenoid subject significant pricing pressure offset increase volume sale vitamin rise sale revenue number product particularly enzyme new product entry exclude medicinal feed additive product sell sale division increase moderately division operate profit margin decline centage point consequently effort improve profitability step division operate profit margin high average comparable competitor major part vitamin case resolve currently review strategic alternative business vitamin fine chemical division consolidate leadership tough market environmentthe vitamin fine chemical division post sale million swiss franc compare pre vious yearsale show growth local currency fall swiss francsthe sale include sale ofmedicinal feed additive mfa productsup date oftheir dis posal exclude mfa sale ofthe division increase local currency swiss francsdespite additional pro ductivity gainson adjust basis operating profit ebitda decline million swiss franc million swiss francsrespectivelythe division operate profit ebitda margin respec tivelyroughly ofthe yearon year decrease profit margin account onetime gain record sale themfa businesswhile rest attributable increase raw vitamin fine chemical division material energy cost low selling price equipped operate difficult highly competitive market thank sale ofvitamin ebcomplex vita minsenzymesdextromethorphan new improved product cough suppressant parsol sunscreen agent show healthy maintain market lead volume growthhoweversome prod markus altwegg head vitamin fine chemical division uct experience continue price ero sionproduct launch year post good growth account ofsale sales europe adversely affect bse problem outbreak foot mouth diseasea europe wide restructuring ofmarkete oper ation enable division reduce cost increase efficiencyin north america sale significantly vitamin fine chemicalsfrom previous yeardespite stag total divisional sale million chf nating demand dietary supple mentsoverallsale growth latin america goodthank strong position aquaculture robust increase vitamin premix sale feed food industry asiapacific region strong vol ume gain largely offset revenue loss weak yenin china adjust basis break ofchicken flucombine high grain price result ofa severe droughthad negative impact sale animal nutrition segment chainegcg constituent ofgreen tea believe benefit pre division compete environ vent cardiovascular disease ment shape increase industrial consolidation compete sup effort develop new application pliersvertical integration globali establish product include collabo sation customer effect ration academic research insti ofmounte political economic tutesone focus ofresearch role uncertainty consumer behaviour ofvitamin reduce risk put pressure onglobal cus osteoporosis tomerspriceswhich inturn attempt shift supplier finallyformulation development group advanced technolo fuel growth research gy new raw material deliver developmentthe division product strong differen focus research development tiating benefit marketplace effort priority strategic investment future new technology imple division mente optimise productionat substantial strategic investment new vitamin plant sisseln switzer secure longterm cost leadership landfor exampleprocesse investment propertyplant employ improve yield equipment total million swiss substantially reduce byproduct waste francs air water emission sisseln construction begin rollout ofnew product theworld largestmost advanced customer segment ofthe divi production facility vitamin sion growth strategyin food theplant operational late pharmaceutical segment annual capacity focus natural productslike tonnescomplemente egcg epigallocatechin gallate investmentcapacity expand ofthe human food atthe plant vitamin intermedi vitamin fine chemical ate lalden switzerland ensure growth low adequate supply sisseln year owe economic slow facility come stream downthedivision objective tocontinue grow fast work complete market ofa multiphase project expand vitamin facility dalry division implement scotlandnot manufactur measure maintain profitability ing capacity increasedbut plant despite margin pressure charac technologically upgrade terise current marketanumber reduce environmental impact ofprogramme place achieve operation therefuture project phase additional savingsparticularly expand capacity furtherwhile purchasing production asiapacific food cosmetic pharmaceutical sale region sale customer segment europe africa north south america animal feed substantially decrease manufactur longterm goal develop ing cost deploy innovativeoptimised manu facturing process halve pro manufacturing scheme employ duction cost ofour key vitamin biotin plant grenzach ger yearsroughly modify meet sharp ofthe division research devel upsurge demand opment budget grenzacha new production facility purpose vitamin complete startup phase fully operational vitamin fine chemi cal division expect sale growth division open new citric acid low singledigit rangeas plant wuxi china capable ofpro continue operate difficult ducing tonne annuallythe economic environmentour goal longterm goal num stabilise division operate ber supplier ofthis product ebitda marginsdespite continued pricing pressuresby focus outlooklooke long termthe profitable market product relevant market vitamin continually improve produc fine chemical division project tivity steady volume growth rate vitamin fine chemicalsin november december theeuropean commission impose fine total million euro million swiss franc vita min caseadequate provision record group assess adequacy ofit remain provision vitamin case december additional provision million swiss franc recorded cover potential liability arise customer lawsuit united states base assump tion outstanding litigation resolve term similar settle ment reach individual civil suitsroche currently review strategic option outside group forthe vitamin fine chemical division vitamin fine chemical aim integrate diagnosistherapy approach optimise treatment gene test doctor determine patient benefit treatment breast cancer drug herceptin write pre scription goal develop integrate healthcare solution far today diagnostic therapeutic possibility solu tion possible detect predisposition earlystage disease stop progress addition approach promise finetune individualised treatment precise treatment monitoringactionable health information thank strong presence pharmaceutical diagnostic roche powerful position develop individualised diagnosis therapy solution disease management project focus mainly viral disease hiv hepatitis initiate roche develop innovative programme variety clinical condition ongoing effort help meet challenge face modern medicine integrate cancer care unit set speed development novel cancer care solution addition crossdivisional committee establish coordinate activity genetic promote knowledge transfer development promise field actionable health information helping identify predisposition diseaseifpredisposition early stage disease detectedindivid ual counsel pre ventive measuressuch modifying lifestyle dietmore sensitive diagnostic technique make possible monitor pro gression ofcertain disease start treatment earlierin additionbetter pretreatment selection improve therapeutic outcome identify patient likely benefit particular treatment medium term new technology spawn genomic apply genebase testing pharmacogenomic analy sis lead treatment customise patientsindividual needsintegrated healthcare solution tailormade medicine benefit patientsthey particularly field oncology help ensure optimum use ofthe fund available healthcare pioneer way combine diagnostic therapeutic benefit patient result continue roche strategy offirmly embed future early detection disease selec integrate healthcare concept tion good medication patient operating divisionsin roche diagnostic create integrated accurate treatment monitoring cancer care unitit task provide new diagnostic test enable optimise therapeutic outcome early cancer detectionassure delivery heino von prondzynski head diagnostic division oftheright drug right patient permit monitor optimal outcomesto strengthen integrate innovation cost integrate cancer care unit capa efficiencyour aim provide inte bilitiesroche diagnostic seek grated healthcare solutionsin order collaboration alliance thiswe develop innovative othercompanie academic insti diagnostic technique extend tution find novel diagnostic therapeutic application ofour phar marker technology strategy maceutical exampleby make anddevelop new clinical validation possible diagnose disease early concept actionable health informationhere ofthe results ofongo cardiocareosteocare andcancer researchdevelopment produc ing implementation ofprogramme care roche expand focus tion site pharmaceutical disease ofthe central nervous system diagnostic divisionsthe new alzheimer diseasedepression centre concentrate cancer amplicor hcv monitor test inflammatory condition research diagnostic rda canbe optimise treatment undertaking project flow hepatitis pegasys combina crossdivisional programme roche vision ofintegrate healthcare tion ribavirinalargescale apply genomicsin recent year solution clinical trial confirm roche increasingly focus highly sensitive reliable test develop competitive advantage iscapable ofmeasuring patient area ofgenetic genomic response therapy soon bring strength startedmake possible predict pharmaceutical diagnostic treatment outcome adjust divisionsaccordinglyin autumn therapy patientsindividual need cancercare launch ofherceptin new paradigm medicine lead grow demand test detect overexpression ofher availability ofspecific diagnostic test possible establish standard target treat predisposition target screening prevention diagnosis therapy monitoring ment ofbreast cancer patient herceptin cardiocare diagnostic test forearly identification ofpatient riskofdevelope heart failure ntprobnp launch set joint program apply aroutine test elecsys system genomics common coordinating test make easy doctor framework divisionsresearch determine patient prognosis activity disciplinesthe aim allow tomonitor treatment promote development ofa cross drug sucha dilatrend divisional culture focus knowl torem edgesharing create opportuni tie intensive collaborative potential synergies diag effortsgiven divisionsestab nostic therapeutic currently lishe expertise type diabete evaluate number ofareas oncologythese area select include use ofneorecormon initial focus ofsupportand bondronat oncologycellcept dedicated work group transplantation medicine set mabthera rheumatoid arthritis october roche dedicate new addition exist programme research centre penzberg germany hivresistancehepcarecmvcare underscoring penzberg importance actionable health information roche set high standard roche sustainability mean health safety environmental operating business protection employee socially environmentally help ensure longterm com responsible way aim patibility activity meet need present human health environment compromise qual worldwide ity life future generationspeople environment modern globally active company face social ecological challenge addition demand marketplacea good corporate citizen roche help find solution company special responsibility employee particu larly true difficult decision strengthen longterm competitiveness case year pharmaceutical division sustainability centre environmental protection activity recognition commitment roche select membership dow jones sustainability world index roche take corporate social responsibility seriously involve wide range community program main focus initiative problem hivaid develop country people environment human resource reshape future growth atthe endof roche group employ people worldwide year beforea result ofthis decrease spinoff ofgivaudan cost ofwage salariessocial security cost ployee benefit decline million swiss franc million swiss franc decrease headcount mainly pharmaceutical division reshape future buona visible sign great growthinitiativelaunche spring end ofthe year total importance roche attache employee position cut worldwide development new training primarily nutley usawel wyn ukbasel switzerland conference centre help promote palo alto usa sitesin close cooper intensive network communication ation employee organisation socially compatible solution conform group worldwide e local legal requirement practice find affect daniel villiger head corporate service employeesin allsome position eliminate end restructure programme human resourcesheadcount diagnostic division headcount division year end rise line division change change good business growth pharmaceutical diagnostic wide range training develop vitamin fine chemical ment opportunitiesqualifiedmoti vate employee decisive factor roche group achieve strategic business objectivesroche offer employee headcount region year end worldclass personal professional europe development opportunitiesdesigne switzerland enhance professional north america interpersonal skillswe attach particu latin america lar importance prepare people asia forinternational leadership role africa australia oceania complex project management task total group level senior manager complete performancebase compensation programmerun cooperation extendednow year london business schoolwhich implementationindividualisedper design develop leadership skill formancebase compensation asimilar programme initiate establish ofthe pharmaceutical division roche corporate cultureall division roll outseveral continue rely thousand pharmaceutical personnel heavily compensation model world receive training reward individual achievement programmethe diagnos promote entrepreneurial thinking tic vitamin fine chemi thecompensation oftop executive cal division special depend considerable extent management development programme individual performancetheir division place group result construction ofroche forum buonas total management new senior management training personnel participate stock conference centre locate option programme award buonas peninsula canton ofzug option roche switzerland progress nonvoting equity security genuss smoothlyit open schedule scheineprice swiss franc spring centre provide eachthe underlie nonvoting executive roche equity security require pro group attractive facility com gramme buy stock prising conference seminar marketand programme wingdine room accommoda result dilution ofthe value tion beautiful set ofroche securitiesroche subsidiary operate additional bonus plan human resource areain focus integrity business transactionsthe aim communicate concept ethical practice equally valid roche company employee defineand preventpoten tial unacceptable practice compromise corporate integrity stock option programme base roche nonvoting equity security ofwhich result dilution value ofroche security roche want manager nonmanagerial staffmore oppor tunity participate group successfor reason cur rently consider way ofextending performancebase executive compen sation introduce scheme enable employee acquire roche nonvoting equity security preferential term behaviour businessas group operate globeroche commit observe high ethical standard ofit business dealing company employee bind roche corporate princi ples localnational interna tional lawsfurther business integrity workshop conduct continue programme design explain company ethical stan dard impart rule behaviour business enable roche employ ee perform task way reproachto dateover employee complete workshop human resourcessafety environmental protection sustainabilityas globally active healthcare grouproche commit put principle ofsustainable development practice responsibly appropriatelyin sowe conscious ofthe dynamic interdepend ence ofeconomicenvironmental social factorsroche abide owncorporate healthsafety envi ronmental protection standard guideline ofthe international council ofchemical association icca chemical industry worldwide responsible care pro roche safety environmental grammein particularwe subscribe precautionary principlethe pol protection policy base luterpay principle principle ofecoefficiency principle sustainable development han knzi head corporate safety environmental protection roche remain committed increa ing ecoefficiency reduce energy consumption associate emission implement process group facility optimisationsin recognition ofit number ofincident decline sustainability performance howeverthree employee injure roche include green explosion company plant investment fund amem germanythe rate ofoccupational ber ofthe dow jones sustainability accident increase pro world index long accidentrelate absencesbut number ofaccident continue expenditure amount declinethis improved performance million swiss francsor dueinno small uncompro ofsaleswith integrate control mising commitment train main investment focus development activity officer employeesone example accident incidentsas previ ofthis workshop conduct ous yearsthere major incident expert safety environmental protection safety environmental protection expenditure millions chf manufacturing process reduce chemical waste continue investment undiminishedhoweverat operating cost ourplant scotlandfor examplea total expenditure switch aconventional chemical process base biotechnology roche groupentitle eliminate anenvironmentally sustainabilitythe main topic problematic chlorinate hydrocarbon resource conservationenergy saving byproduct ofthe old process reduction ofco emission year consumption audits perform atroche facility ofsubstances countriesthe result confirm deplete ozone layer high standard ofsafety reduce replace halo environmental protection meet genate hydrocarbon sub groupparticular stance alternative technical solu attention pay year audits tionswe help protect occupational health safety ozone layer reduce global warming workplace environmental stewardshiproche see start ofa number remain actively involve national ofinitiative ofthe responsible international organisation work care programmeincluding special ing improve safe management campaign accident prevention ofchemicalssuch sgcioecd warehouse safety coordination icca ceficlast year roche contractor complete test offour high pro duction volume chemicalspart ofits environmental protectionfurther contribution programme design advance energy conservation evaluate environmental impact wereachieve thank campaign improve knowledge groupdespite slight substance worldwide large rise production output chemical quantitiesroche expert currently manufacturingwhich particularly evaluate substance energy materialintensivetotal group major contributor energy consumption group facili international chemical indus tie reduce try longrange research initiative increase use offuel oil aim increase understand coal result high emission ofthe way chemical inter sulfur dioxide nitrogen act human bodyanimal oxideshoweverby contrastoverall environment emission ofvolatile organic com pound vocs group facility remain lowtotal chemical waste slightly result ofthe high production outputour effort steadily increase ecoefficiency safety environmental protectionsocial involvement social involvement long tradi tion rochewe honour respon sibilitie society play active role different areasfrom humanitarian aid education awarenessraising campaign health issue environmental stewardship support artsas health care companyroche spe cial contribution fight pro mote health overcome diseasein social initiative focus par ticularly problem ofhivaid develop country recognise industry global fight hivaid responsibility society ofthe great challenge pose hivaid devastation develop new medication cause ofafrica year roche cooper world develop country asany number ofstudie project ate international organisation analyse shownpeople living programme combat problem hiv country face major obstacle limit access carethe cause hiv country dissemination share ofknowl edge level critical pre world venting manage hiv infection franz humer chairman board directors ceo anddiseasein develop country social involvement commitment research hivaid profit sale ofmedicine hiv relentless adversary new treatment new mechanism action hivaid country urgently need fight multiresistant strain virus roche involve search antihiv medicine group partnership principle commit major contribution advance treatment diagnosis hiv infec ment cooperation essential tion aid roche continues invest substantial amount money scien make access programme tific manpower discover develop new antihiv medicine develop world successthe fol patent allow recoup enormous cost involve research low ofthe proj continue new drug investigate hiv fusion inhibitor ect support worldwide roche roche iscodeveloping trimeris currently furthest clinical bluesky initiative help people trial represent new approach fight virus offering hope infect hiv indirect grow number hivinfecte patient long respond exist drug victim ofhiv aids partnership pharmaccess internationalroche work globe roche create ofthe basic condition itspart fight hivaids necessary comprehensive hiv support numerous project carein africawe provide con help hiv patient people trolledsustainable assistance focus life indirectly affect ing building improve local pandemic medical infrastructureslaunche early pilot project aim expand access price dis improve treatment access countsroche found member people hiv kenyauganda ofthe accelerate access initiative cte divoire senegalsupplie aaia collaborative project launch late medicine hiv number ofun organisa opportunistic infectionstraining pro tionsinclude world bankthe gramme health professional world health organization andpatient education key element unaid united nations chil ofthis partnering initiativewhich drens fund unicefin partnership fully fund rochewith local government industryone fund financial support ofthe main objective ofthe initiative international communitythis ini find practical way partici tiative ultimately expand pant work closely reach far people improve access care treat ment people hiv aids thailand roche participate develop country international collaborative pro gramme aim specifically develop price reduction e sustainable solution improve access care real difference people live roche supply discount antihiv hivthe programme investi medicine country subsaharan gate efficacy safety africa nation desig variousantihiv treatment regimen nate develop thai patient local condi countrieswe feel duty tionsthank support compa social involvementnie like rochemedicine available cost study participantswho continue receive effective antihiv treatment study complete sight life sight life nonprofit humanitarian programme found fund roche support fight vitamin deficiency develop country estimate million child age risk develop condition year half million young child vitamin deficiency blind majority die complication year vita min important healthy vision need normal growthand play key role regulate cell division build resistance infection task force sight life support project africa asia latin america include technical assistance project support scientific research effort year focus develop tech nical aid instruction material medical paramedical training pro gramme vitamin capsule distribute million people free charge capsule manufacture especially sight life areuse primarily prevention programme useful treat acute vita min deficiency social involvement finance slow start roche significantly improve performance underlie operating business result strong sale growth pharmaceutical fast expect cost saving restructuring programme reshape future growththus programme achieve payback yearthe operate profit margin underlie pharmaceutical business improve percentage point close target range diagnostic continue grow doubledigit rate improve profitability furtherfor treasury operation difficult yearthe decline world stock market lead reduce financial resultonce roche produce strong positive cash flow operating activity remain solidly finance financefinancial review highlight millions chf figure report figure report financial statement adjust basis change change sale ebitda operating profit net income roche achieve report net income billion swiss franc decrease previous year decrease entirely special item million swiss franc pharmaceutical division restructuring cost million swiss franc expense vitamin case nonrecurrence billion swiss franc pretax gain sale genentech share underlie operating result continue improvement increase sale pharmaceutical diagnostic improve ongoing cost struc ture operating profit adjust basis exclude effect special item increase billion swiss franc adjust net income billion swiss franc improve operating performance offset reduce financial result increase tax expense improve transparency group result financial statement include additional disclosure breakdown pharmaceutical division roche prescription genentech prescription otc detailed split financial income cash flow operating activity billion swiss franc million swiss franc financing activity reduce debt billion swiss franc reinveste marketable security net liquidity increase million swiss franc billion swiss franc liquid fund ongoing cash flow generation support strengthen roche unique healthcare company hightech pillar erich hunziker chief financial officer financial review income statement millions chf figure report figure report financial statement adjust basis change change sale cost sale gross profit marketing distribution research development administration amortisation intangible asset impairment longterm asset pharmaceutical division restructuring impairment longterm asset restructuring cost operate income expense net gain sale genentech share vitamin case operating profit financial income expense net profit taxis income taxis profit taxis change accounting policy income applicable minority interest share result associate company net income dilute earning share nonvoting equity security chf adjust figure internal management roche group represent result group underlie ongoing operation exclude special item include continue business page description reconciliation financial reviewresult report consolidated financial statementsin millions chf operating profit decrease impact special item operating profit decrease billion swiss franc operating result include month result fragrance flavours division addition net operating income billion swiss franc arise special item notably billion swiss franc gain sale genentech share billion swiss franc impairment charge arise change accounting policy table operating profit include net operating expense billion pharmaceutical division restructure vitamin case exclude item operating profit increase billion swiss franc isdiscusse commentary adjust result pharmaceutical division restructuring nonrecurre cost million swiss franc incur implementation pharmaceutical division reshape future growth programme previously indicate total restructuring cost estimate atapproximately billion swiss franc approximately noncash impairment charge programme lead significant improvement cost structure asdescribe vitamin case base development litigation recent settlement negotiation mainly united states group record additional provision million swiss franc reflect term settlement achieve recently number individual civil case litigation process new litigation arise possible final obligation different net income decrease impact special item factor cause decrease operating profit lead large decrease net income addition financial income include gain million swiss franc arise disposal associate company income taxis include tax effect special item onetime gain arise change accounting policy exclude item net income decrease billion swiss franc discuss commentary adjust result result adjust basisin million chf sale increase sale doubledigit growth diagnostic exclude fragrance flavour division spin mid adjust salesincrease pharmaceutical sale grow particularly good performance new product mabtherarituxan herceptin xeloda robust sale longerestablishe product cellcept kytril acquire end contribute sale offset impact patent expiry verseddormicum delist draganon japan diagnostic show strong doubledigit sale growth drive molecular diagnostic diabetes care relative fall sale vitamin finechemical inclusion medicinal feed additive mfa product sell comparative figure exclude mfa sale increase increase volume financial review sale change change local chf currency pharmaceutical diagnostic vitamin fine chemicalsa sale adjust basis fragrance flavours reclassificationa total sale vitamin fine chemical division sale adjust include reclassification million swiss franc sale fragrance flavour division half prior spinoff vitamin fine chemical division sale include sale medicinal feed additive mfa product date disposal exclude mfa vitamin fine chemical sale increase local currency chf operating profit increase ongoing operation operating profit increase billion swiss franc adjust basis exclude fragrance flavours special item table increase primarily drive sale growth significantly improve cost structure result reshape future growth initiative operate profit percentage sale improve percentage point result achieve spite result include million swiss franc gain continue product portfolio asset realignment respect sale north american right coreg mfa product reoccur gross profit increase billion swiss franc gross profit margin improve percentage point reflect particularly strong growth highmargin pharma ceutical product diagnostic business area productivity improvement division andthe effect pharmaceutical division reshape future growth initiative improvement achieve spite continue pressure price particular vitamin fine chemical new generation product diagnostic increase production service cost marketing distribution decrease billion swiss franc year rise half year beneficial effect reshape future growth initiative allow focused spend growth area whilst increase sup port key growth driver support new product launch pharmaceutical diagnostic marketing distribution percentage sale fall percentage point research development decrease billion swiss franc growth research development expense genentech diagnostic support strong research devel opment pipeline new strategic alliance collaboration inlicense agreement offset reduce expenditure roche prescription reflect intensive review development portfolio impact reshape future growth initiative research development cost percentage sale group level decline pharmaceutical account group research development expense theydecrease administration increase billion swiss franc sale growth result continuous efficiency improvement impact reshape future growth initiative financial reviewamortisation intangible asset amortisation expense increase additional amortisation follow acquisition kytril december roche amortisation charge currently sale continue significantly high industry average primarily goodwill arise growth acquisition accounting treatment acquisition international accounting standard impairment longterm asset exclude impairment entry record arise implementation reshape future growth programme significant impairment entry operate income expense net swing approximately billion swiss franc income million swiss franc expense million swiss franc major factor increase net royalty expense particular diagnostic exchange loss receivables devaluation turkish brazilian argentine currency addition figure include approximately million swiss franc gain ongoing realignment product portfolio financial income anticipate net financial income billion swiss franc similar level halfyear decline world market negative impact group financial income period despite group generate sufficient financial income cover group financial expense consist mainly interest cost net income equity investment billion swiss franc include billion swiss franc gain sale labcorp share june decline compare reflect difficult market condition interest expense billion swiss franc broadly level previous year interest expense particularly amortisation debt discount tend volatile element net financial income order increase transparency group financial result information composition net financial income note consolidated financial statement expand income taxis increase effective tax rate operating income make considerably high proportion pretax income case previous year lead increase group effective tax rate operating income typically occur jurisdiction high tax rate compare finan cial income furthermore financial income include gain sale labcorp share taxable united states consequently adjusted pretax income high tax charge high associate company minority interest currently significant impact group result expense minority interest continues increase overall contribution genentech net income increase income associate company consist mainly income labcorp period prior june time account associate company remain associate company relatively minor effect net income decrease adjust basis net income low billion swiss franc increase operating profit offset slightly low financial income proportionately high tax charge financial review divisional result adjust basis million chf divisional ebitda operate sale operating profit party ebitda sale profit sale pharmaceutical total prescription roche prescription genentech prescription otc diagnostic vitamin fine chemical group total pharmaceutical total prescription roche prescription genentech prescription otc diagnostic vitamin fine chemical group total adjusted figure internal management roche group represent result group underlie ongoing operation exclude special item include continue business seepage description reconciliation ebitda earning interest financial income tax depreciation amortisation include impairment correspond operate profit depreciation amortisation include impairment pharmaceutical improve margin pharmaceutical sale local currency increase particularly strong sale oncology product cellcept pharmaceutical operating profit grow billion swiss franc high sale considerably improve cost structure result reshape future growth initiative ebitda pharmaceutical division increase operate profit margin improve percentage point ebitda margin percentage point reshape future growth initiative progress fast expect cost saving estimate order million swiss franc effect measure annual cost saving approximately million swiss franc realise restructuring cost million swiss franc recognise financial statement comprise employee cost million swiss franc impairment charge relate closure certain operation million swiss franc cost total restruc ture cost estimate approximately billion swiss franc approximately noncash impairment charge enhance comparability restructuring cost exclude adjusted result financial reviewtotal prescription prescription drug sale roche genentech increase local currency swiss franc billion swiss franc operating profit high operating margin improve sale roche prescription sale rise local currency swiss franc operating profit higher main positive factor high sale favourable impact reshape future growth initiative considerably improve cost structure offset additional amortisation follow acquisition kytril million swiss franc gain sale north american right coreg comparative genentech prescription sale improve billion swiss franc growth swiss franc asin local currency operating profit reach million swiss franc equivalent sale turnaround operating loss strongsale growth spite high cost support growth genentech oper ating result include million swiss franc amortisation mainly arise acquisition accounting ebitda total million swiss franc sale slightly ahead level otc sale rise local currency sale swiss franc show slight decline billion swiss franc modest sale growth ahead market growth oper ate profit margin amount achieve aggressive focus cost control spite substantially increase foreign exchange loss receivables diagnostic strong result sale development diagnostic division significantly outperform market overall growth rate local currency division market leader diagnostic allfive business area division apply science molecular diagnostic centralize diagnostic near patient testing diabete care grow fast market strong sale growth roche diagnostic achieve doubledigit increase operate profit million swiss franc ebitda grow doubledigit rate million swiss franc operating profit margin increase percentage point ebitda margin percentage point vitamin fine chemical ongoing price pressure sale vitamin fine chemical division stable local currency exclude medicinal feed additive mfa product sell sale increase local curren cie vitamin fine chemical operating profit ebitda drop approximately million swiss franc million swiss franc respectively approximately decrease inclusion figure onetime gain sale mfa product remain increase raw material energy price somewhat low selling price result consist cost corporate headquarters financial review balance sheet million chf change longterm asset current asset total asset equity minority interest noncurrent liability current liability total equity minority interest liabilitie foreign currency translation effect movement balance sheet position combination factor movement foreign currency exchange rate effect balance sheet position asset liability group company report foreign currency notably dollar euro translate swiss franc yearend rate effect expect likely continue increase especially alliance chugai result increase group balance sheet japanese yen base currency marketable security derivative book fair value follow implementation new international accounting standard major change accounting policy relate treatment financial instrument signifi impact group firstly derivative report balance sheet fair value gain loss include financial income secondly availableforsale mar ketable security investment record market value change market value record equity realise point include financial income fall world stock market unrealise net loss net tax minority interest billion swiss franc record equity december give overall level group marketable security investment billion swiss franc represent net unrealised loss approximately end year compare net unrealised gain begin year provision litigation november december european union announce fine total million euro million swiss franc respect vitamin case adequate provision amount record amount pay discuss group record provision million swiss franc respect vitamin case addition provision ongoing litigation notably igen discuss note consolidated financial statement amount record management good estimate base currently available information litigation process new liti gation arise possible final obligation different total provision isnot disclose prejudice group position current litigation offbalance sheet financing group offbalance sheet financing group subsidiary genentech enter synthetic lease structure certain facility discuss note consolidated financial statement report onbalance sheet increase property plant equipment billion swiss franc correspond increase short term longterm debt group operating result include year depreciation charge facility financial reviewreinvestment positive cash flow cash generate operation reinveste group marketable security port folio cause billion swiss franc increase current asset cash flow net liquidity million chf cash flow statement operating activity income taxis income taxis pay activity operating activity financing activity invest activity net effect currency translation cash increase decrease cash group continue strong cash generation pretax cash generate operation billion swiss franc mainly drive strong ebitda financing significant cash flow billion swiss franc proceed lyon bond issue july billion swiss franc repayment maturity bull spread bond general reduction longterm bank borrowing group pay billion swiss franc dividend april significant investing cash flow billion swiss franc proceed sale labcorp share june capital expenditure continue previous level major acquisition divestment fund immediately require reinveste group marketable security portfolio cash flow state ment give note consolidated financial statement net liquidity december january cash marketable security investment derivative financial instrument net equity instrument financial asset longterm debt shortterm debt total debt net liquidity group revise definition net liquidity follow recent change accounting policy net liquidity define financial asset market value debt liability increase year million swiss franc billion swiss franc thereinvestment cash generate partly offset fall global stock price affect market value marketable security equity instrument billion swiss franc debt genentech synthetic lease include balance financial review subsequent event majority hold chugai december roche chugai announce enter alliance create lead researchdriven japanese pharmaceutical company alliance subject approval chugais shareholders appropriate regulatory authority willsee merger chugai roche japanese pharmaceuticals subsidiary nippon roche alliance expected complete late roche majority shareholder interest purely account term chugai account fully consolidate subsidiary roche group minority interest similar way genentech currently report roche significant effect acquisition accounting include ongoing impact amortisation goodwill intangible asset fair value adjustment vitamin fine chemical division group reassess strategic option development vitamin fine chemical division discuss note consolidated financial statement theannouncement detailed formal plan group continue account divisionaspart continue operation sale labcorp share february labcorp file registration statement announce group plan offer sale million share labcorp option sell million share cover overallotment assume total million share sold roche ownership interest labcorp reduce approximately approxi mately amortisation goodwill follow implementation recent change company united states generally accept accounting principle gaap long require amortise goodwill instead carry regular impairment review roche continue amortise goodwill asrequire international accounting standard ias expect charge approximately million swiss franc financial reviewforeign exchange rate exchange rate swiss franc december average december average december usd eur gbp jpy chfusd exchange rate financial review adjust basis concept adjust basis management view group ongoing operation present consistent comparable basis consolidated result roche group significantly influence special item change international accounting standard year improve visibil ity underlie business adjust result present adjust result internal management business represent result group underlie ongoing operation principle compile adjust result apply consistent basis major concept follow adjust result include gain loss continue product portfolio asset realignment sale income newly acquire product impact sale income patent expiry withdrawal disposal exist product impairment longterm asset major restructuring cost normal ongoing restructuring gain loss sale marketable security adjust result exclude discontinue operation sale spinoff business onetime cost major restructure fundamental reorganisation charge exceptional legal case gain loss arise disposal fully consolidate subsidiary associate company transition effect change accounting policy specific item exclude adjusted result adjust result exclude nonrecurre cost pharmaceutical division restructure additional charge respect vitamin case adjust result exclude result fragrance flavour division prior givaudan spinoff june gain sale genentech share gain sale labcorp share october impact fair value adjustment genentech inventory arise acquisition transition effect new impairment policy credit change accounting policy financial reviewreconciliation report figure adjust basisin million chf reference number indicate corresponding note consolidated financial statement sale operating year end december party ebitda profit net income report financial statement major restructuring nonrecurre cost reshape future growth initiative legal case additional charge respect vitamin case income taxis result adjust basis sale operating year end december party ebitda profit net income report financial statement discontinue operation result fragrance flavour division prior givaudan spinoff reclassification intercompany sale fragrance flavour division sale party gain loss fully consolidate subsidiary associate company gain reduction ownership genentech gain reduction ownership labcorp impact fair value adjustment genentech inventory transition effect change accounting policy impairment longterm asset business combination intangible asset income taxis income applicable minority interest result adjust basis financial review consolidated financial statement reference number indicate corresponding note consolidated financial statement consolidated income statement million chf year end december sale cost sale gross profit marketing distribution research development administration amortisation intangible asset impairment longterm asset pharmaceutical division restructuring impairment longterm asset restructuring cost operate income expense net gain sale genentech share vitamin case operating profit financial income expense net profit taxis income taxis profit taxis change accounting policy income applicable minority interest share result associate company net income basic earning share nonvoting equity security chf dilute earning share nonvoting equity security chf figure include result fragrance flavours division givaudan spinoff june note number share share information restate share split take place seenote consolidated financial statementsconsolidate balance sheet millions chf december longterm asset property plant equipment intangible asset investment associate company investment defer income tax asset longterm asset total longterm asset current asset inventory account receivable trade current income tax asset current asset marketable security cash cash equivalent total current asset total asset equity share capital nonvoting equity security genussscheine equity instrument retain earning total equity minority interest noncurrent liability longterm debt defer income tax liability liabilitie postemployment benefit provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable trade accrue current liability total current liability total equity minority interest liability pro memoria nonvoting equity securities nominal value note consolidated financial statement consolidate statement change equity million chf year end december share capital balance january december nonvoting equity security genussscheine balance january december equity instrument balance january previously report change accounting policy balance january restate movement year balance december retain earning balance january change accounting policy balance january restate net income dividend pay givaudan spinoff special dividend transfer net asset change fair value reserve net equity component new convertible debt currency translation gain loss balance december total equity december pro memoria nonvoting equity securities nominal value note consolidated financial statementsconsolidate cash flow statement million chf year end december cash flow operating activity cash generate operation increase decrease work capital cost vitamin case pay cost pharmaceutical division restructuring pay cost genentech legal settlement pay restructuring cost pay payment define benefit postemployment plan operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow financing activity proceed issue longterm debt repayment longterm debt transaction equity instrument increase decrease shortterm borrowing interest dividend pay givaudan spinoff special dividend givaudan cash balance finance cash flow total cash flow financing activity cash provide operating financing activity cash flow invest activity purchase property plant equipment intangible asset disposal property plant equipment intangible asset acquisition subsidiary associate company product divestment subsidiary associate company product interest dividend receive purchase marketable security net sale total cash flow investing activity net effect currency translation cash increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year figure include cash flow fragrance flavours division givaudan spinoff june note consolidated financial statement note consolidated financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international accounting standard prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve forissue board director february preparation consolidated financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change consolidation policy financial statement consolidate financial statement roche holding ltd acompany register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enter prise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right company share capital company acquire year consolidated date oper ate control transfer group subsidiary divest include date divestment company acquire resold consolidated classify asset hold sale carry fair value asset identify divestment follow year reclassify asset hold sale current asset asset normally consist mainly inventory property plant equipment longterm asset investment associate company account equity method compa ny group exercise significant influence control normally evidence group own voting right company inter est joint venture report linebyline proportionate consolidation method foreign currency translation group company maintain financial record local currency certain group company maintain financial information group report purpose dollar swiss franc euros measurement currency company concern local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss monetary asset liability denominate currency include income deferred equity qualifying cash flow hedge note consolidated financial statementsupon consolidation asset liability group company measurement currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity divestment foreign entity identify cumulative currency translation difference relate foreign entity recognise income gain loss divestment revenue cost sale sale represent amount receive receivable good supply service render customer deduct volume discount sale taxis revenue sale product recognise transfer customer significant risk reward usually shipment royalty income recognise accrual basis accordance economic substance ofthe agreement receipt upfront milestone payment similar nonrefundable payment relate sale licensing product technology initially report deferred income recognise income period development collaboration manufacturing obligation revenue record earn service perform cost sale include correspond direct production cost relate produc tion overhead good manufacture service render research development research cost charge income incur exception building major item equipment capitalise depreciate development cost milestone payment similar nonrefundable upfront product licence payment capitalise intangible asset probable future economic benefit flow group amortise straightline basis period expect benefit review impairment balance sheet date development cost charge income incur criterion recognition asset meet employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned group operate number define benefit define contribution plan world cost year define benefit plan determine project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return plan asset discount rate base market yield highquality corporate bond country concern difference assumption actual experience effect change actuarial assumption allocate estimate average remain work live employee difference exceed define corridor past service cost allocate average period benefit vested pension asset liability different define benefit scheme offset group legally enforceable right use surplus plan settle obligation plan pension asset recognise extent group able derive future economic benefit way refund plan reduction future contribution group contribution define contribution plan charge income statement year relate note consolidated financial statement taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base onincome property capital taxis include operating expense financial expense accord nature provision income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary current inten tion remit earning defer income taxis provide liability method defer income taxis recognise temporary difference tax basis asset liability carry value financial reporting purpose defer income tax asset relate carryforward unused tax loss recognise extent probable future tax able profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy taxation authority legally enforceable right offset property plant equipment property plant equipment initially record cost purchase construction depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow building land improvement year machinery equipment year office equipment year motor vehicle year investment grant similar assistance project initially record deferred income inoth noncurrent liability subsequently recognise income useful life relate asset repair maintenance cost recognise expense incur borrowing cost capitalise asset acquire finance lease depreciate estimate useful life payment operating lease charge income straightline basis period lease intangible asset business combination goodwill record intangible asset surplus cost acquisition fair value identifiable asset acquire goodwill fair value adjustment treat asasset liability acquire company record local currency company patent licence trademark intangible asset initially record fair value asset acquire business combination fair value allocate acquisition accounting acquire business combination initial fair value cost note consolidated financial statementsall intangible asset amortise useful life straightline basis estimate useful life major class intangible asset follow goodwill year patent licence trademark low legal duration intangible asset economic useful life maximum year impairment longterm asset recoverable asset high net selling price value inuse carrying carry reduce recoverable value reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate pro jection subsequent year discount appropriate longterm pretax interest rate impairment arise useful life asset question review ifnecessary future depreciationamortisation charge accelerate inventory inventory state low cost net realisable value cost determine firstout method cash cash equivalent cash cash equivalent comprise cash hand time current balance bank similar institution readily convertible know amount cash subject insignificant risk change value definition cash flow statement equity instrument group holding equity instrument record deduction equity theoriginal cost acquisition consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet obligation arise respect certain group debt instrument debt instrument debt instrument initially report cost proceed receive net transaction cost subsequently report amortise cost effective interest method tothe extent debt instrument hedge qualify fair value hedge hedge element record fair value discount net proceed receive principal value redemption amortise duration debt instrument isrecognise interest expense income statement issue convertible debt instrument cost liability portion initially calculate market interest rate equivalent nonconvertible instrument remainder net proceed allocate equity conversion option report equity defer income taxis liabilitie liability element subsequently report amortise cost amortisation debt discount release defer tax liability recognise income statement duration debt instrument value equity conversion option change future period limited conversion prefer stock substance financial liability equity instrument classified longterm debt balance sheet relate dividend payment treat interest expense note consolidated financial statement provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate provision record estimate ultimate liability expect arise take account foreign currency effect time value money contingent liability record existence obligation confirm future event obligation measure reasonable reliability fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price adjust estimate transaction cost incur actual transaction use establish estimation technique option pricing model estimate discount value cash flow fair value balance sheet date approximately line report carry value specifi cally mention note consolidated financial statement international accounting standard revise new standard issue international accounting standard committee interpretation standing interpretation committee effective january principal item affect group standard financial instrument recogni tion measurement effect describe accounting effect new standard implement effective january accord ance transition arrangement standard comparative financial statement restate effect implementation opening balance show table net assetsin millions chf investment marketable security derivative financial instrument defer income taxis minority interest total increase net asset equityin millions chf retain earning total increase equity necessary balance sheet comparative reclassify extend previously report result account presentational change change previously report income statement comparative note consolidated financial statementsfinancial asset financial asset principally investment include marketable security classify heldfortrade availableforsale heldtomaturity originate group heldfortrade investment acquire principally generate profit shortterm fluctuation price heldtomaturity investment security fix maturity group intent ability hold maturity investment originate group loan longterm financial asset create group acquire issuer inaprimary market investment consider availableforsale investment initially record cost include transaction cost purchase sale recognise settlement date heldfortrade investment subsequently carry atfair value change fair value record financial income expense period arise heldtomaturity investment subsequently carry amortise cost effective interest rate method availableforsale investment subsequently carry fair value change fair value record equity availableforsale investment sell impair dispose cumulative gain loss previously recog nised equity include financial income expense current period group previous accounting policy longterm investment carry cost permanent diminution value marketable security value low cost market value derivative derivative financial instrument initially record cost include trans action cost derivative subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense period arise group previous accounting policy gain loss derivative financial instru ment hedge potential exchange rate exposure defer offset loss gain specific transaction hedge fee agree establish contract amortise duration contract gain loss derivative finan cial instrument hedge potential interest rate exposure recognise adjustment interest expense gain loss derivative financial instrument trading pur pose take income arise hedge purpose hedge accounting hedging relationship type fair value hedge hedge particular risk change fair value recognise asset liability cash flow hedge hedge particular risk change time future cash flow hedge net investment foreign entity hedge particular risk change carry value net asset foreign entity qualify hedge accounting hedging relationship meet strict condition ondocumentation probability occurrence hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income expense note consolidated financial statement qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense qualify cash flow hedge hedge instrument record fair value portion change fair value effective hedge include equity remain inef fective portion report financial income expense hedge relationship hedge firm commitment highly probable forecast transaction cumulative change fair value hedge instrument record equity include initial car rye value asset liability time recognise qualify cash flow hedge cumulative change fair value hedge instrument record equity include financial income expense time forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion record financial income expense hedge instrument derivative equity case entity dispose cumu lative change fair value hedge instrument record equity include financial income expense time disposal change effective january revise new standard interpretation effective january themost significant follow impairment asset effective january group recognise impairment charge million swiss franc relate acquire intangible asset reduction defer tax liabil itie million swiss franc record give net charge million swiss franc consolidated result intangible asset business combination effective january group record certain reclassification adjustment original purchase accounting allo cation reflect revise balance result credit income net tax minority interest million swiss franc change fully describe consolidated financial statement note consolidated financial statement financial risk management financial risk management group govern policy guideline approve senior management policy guideline cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policy guideline cover area cash management investment excess fund raise short longterm debt group company report detail financial instrument outstanding financial liquidity togroup treasury monthly basis new post financial risk manager create oversee compliance group financial risk management policy guideline group accordance risk management guideline continue monitor risk deem appropriate certain risk significantly alter use financial instrument derivative group management believe order create optimum value group desirable eliminate mitigate possible market fluctuation addition group management wide discretion undertake contract result significant trading position change value market price change foreign exchange risk group operate world expose movement foreign currency affect ingit net income financial position express swiss franc group continue tomonitor currency exposure appropriate enter transaction aim ofpreserve value asset commitment anticipate transaction group use forward contract foreign currency option optimise certain anticipate foreign exchange revenue cash flow financing transaction transaction exposure arise local currency pay receive trans action denominate foreign currency vary change exchange rate group company income primarily local currency significant expen diture especially purchase good resale interest repayment loan foreign currency similarly transaction exposure arise net balance monetary asset hold foreign currency group company manage exposure local level necessary mean financial instrument option forward contract addition group treasury monitor total worldwide exposure help comprehensive datum receive amonthly basis translation exposure arise consolidation foreign currency denominate finan cial statement group foreign subsidiary effect group consolidated equity show currency translation movement group hedge significant net investment foreign currency take foreign currency loan issue foreign currency denominate debt instrument major translation exposure monitor regular basis significant group cash outflow research development production admin istration denominate swiss franc small proportion group cash inflow swiss franc denominate result increase value swiss franc rela tive currency adverse impact consolidate net income similarly relative fall value swiss franc favourable effect result publish swiss franc note consolidated financial statement interest rate risk interest rate risk arise movement interest rate adverse effect group net income financial position change interest rate cause variation interest income expense interestbeare asset liability addition affect market value certain financial asset liability instrument describe follow section market risk interest rate group major debt instrument fix describe note reduce group exposure change interest rate group company manage shortterm interest rate risk local level necessary financial instrument interest rate forward contract swap option market risk change market value certain financial asset liability instrument affect net income financial position group longterm investment hold strategic pur pose marketable security hold fund management purpose risk loss value reduce review prior invest concentration investment continuous monitoring performance investment change risk configuration investment equity fix income instrument enter basis approve guideline regard liquidity credit rating credit risk credit risk arise possibility counterparty transaction unable unwilling meet obligation cause financial loss group trade receivables subject policy active risk management focusse assessment country risk credit availability ongoing credit evaluation account monitor procedure significant concentration trade receivables counterparty credit risk group large number customer wide geographical spread country risk limit exposure continuously monitor exposure financial asset credit risk control set policy limit credit exposure highquality counterpartie ongoing review credit rating limit individual aggregate credit exposure accordingly liquidity risk group company need sufficient availability cash meet obligation individual company responsible cash management include shortterm investment cash surplus raise loan cover cash deficit subject guidance group certain case approval group level group maintain sufficient reserve cash readily realisable marketable security meet liquidity requirement times addition strong international creditworthiness group allow efficient use international capital market financing pur pose note consolidated financial statement group organisation overview operating subsidiary associate company include page addition operating company group hold finance company chugai december roche chugai announce enter alliance create lead researchdriven japanese pharmaceutical company alliance merger chugai group japanese pharma subsidiary nippon roche transaction account purchase method accounting newly merge company know chugai fully consolidate subsidiary roche group minority interest new company list tokyo stock exchange thetransaction subject approval chugais shareholders appropriate regulatory authority expect complete late group announce public tender offer chugais outstanding share capital term alliance group subscribe additional new share newly merge company group ownership amira november group acquire share capital amira medical inc amira amira company active diabete monitor base united states net consideration pay million swiss franc allocate follow net asset acquiredin million chf goodwill intangible asset defer income taxis provision net asset liability total follow acquisition restructuring programme announce result restructuring charge million swiss franc record operate income expense net note restructure programme substantially complete june transaction march group sell million share genentech public offering yield proceed million dollar million swiss franc result pretax gain incidental cost million swiss franc december group acquire global right kytril million swiss franc december group sell exclusive right coreg united states canada million swiss franc gain sale million swiss franc note consolidated financial statement segment information millions chf divisional information roche genentech total prescription prescription otc pharmaceutical segment revenue segment revenuedivisional sale interdivisional sale divisional sale party segment resultsoperate profit segment asset liabilitie divisional asset segment asset segment asset nonsegment asset total asset divisional liability segment liability segment liability nonsegment liability total liability segment information capital expenditure depreciation amortisation impairment longterm asset research development cost share result associate company investment associate company number employee group division pharmaceutical diagnostic vitamin fine chemical fragrance flavour division spunoff note disclosure pharmaceutical division expand include reportable segment roche prescription genentech prescription otc segment consist cost corporate headquarters reasonably attribute report segment transfer price interdivisional sale set onan arm length basis divisional asset consist primarily property plant equipment goodwill intangible asset receivables inventory divisional liabili tie consist trade account payable segment asset liability consist asset liability reasonably attribute report business segment include pension asset liability provision nonsegment asset liability mainly include current defer income tax balance financial asset liability principally cash marketable security investment associate company investment debt note consolidated financial statementsvitamin continue fragrance diagnostic fine chemical operation flavour group capital expenditure comprise addition intangible asset include goodwill addition property plant equipment include arise acquisition roche prescription segment result include million swiss franc expense respect pharmaceutical division restruc ture include million swiss franc impairment expense note vitamin fine chemical result include million swiss franc expense additional charge respect vitamin case note roche prescription segment result include million swiss franc impairment expense follow implementation new international accounting standard note genentech prescription segment result include million swiss franc gain sale genentech share million swiss franc expense respect fair value adjustment inventory follow acquisition genentech share capital note consolidate financial statement geographical information sale party destination segment asset capital expenditure switzerland european union rest europe europe north america latin america asia africa australia oceania segment total nonsegment asset consolidate total switzerland european union rest europe europe north america latin america asia africa australia oceania segment total nonsegment asset consolidate total segment asset include property plant equipment goodwill intangible asset receivables inventory andother asset reasonably attribute report business segment nonsegment asset mainly include current defer income tax balance financial asset principally cash marketable security investment associated company investment capital expenditure comprise addition intangible asset include goodwill addition property plant equipment include arise acquisition note consolidated financial statement vitamin case follow settlement agreement department justice pricing practice vitamin market overall settlement agreement class action suitbrought buyer bulk vitamin group record provision respect vitamin case provision group well estimate time total liability arise take account currency movement time value money provision legal fee record separately november december european union announce fine total million euro million swiss franc respect vitamin case appropriate provision amount record december group reassess adequacy remain provision vitamin case base development litigation recent settlement negotiation mainly inthe united states direct customer previously opt settlement group record additional provision million swiss franc reflect term settlement achieve recently number individual civil case total provision liability group expect pay adjust foreign currency translation effect time value money assessment base currently available information litigation process new litigation arise possible final obligation different total provision disclose prejudice group position current litigation net cash outflow million swiss franc net cash inflow million swiss franc pharmaceutical division restructuring group announce reshape future growth initiative major restruc ture pharmaceutical division objective improve longterm profitability division increase sale improve division cost structure group announce approximately job reduction follow year conjunc tion closure reorganisation certain facility principally switzer land restructuring cost million swiss franc charge consist employee cost million swiss franc impairment charge million swiss franc relate closure certain operation closure cost million swiss franc netof gain curtailment postemployment define benefit plan million swiss franc note employee closure cost million swiss franc pay december andthe remain million swiss franc include liability balance sheet december givaudan spinoff millions chf june groups fragrance flavours division spin independent company givaudan share givaudan distribute date special dividend holder roche share nonvoting equity security result spinoff asset total billion swiss franc liability total billion swiss franc transfer givaudan note consolidated financial statement result cash flow fragrance flavour division spinoff june include consolidated figure consolidated balance sheet show spinoff include division asset liability sale result asset liability net cash flow fragrance flavour division aspart roche group show discontinue operation follow table continue operation discontinuing operation group group statement income sale interdivisional salesa sale party expense operate profit financial income expense net result taxis income taxis result taxis change accounting policy minority interest share result associate company net income balance sheet december property plant equipment intangible asset longterm asset current asset total asset longterm debt noncurrent liability current liability total liability net asset statement cash flow operating activity financing activity invest activity net effect currency translation cash increase decrease cash transfer price interdivisional sale set arm length basis note consolidated financial statement employee benefitsin millions chf wage salary social security cost postemployment benefit define benefit plan postemployment benefit define contribution plan employee benefit total employee remuneration charge employee benefit include relevant expenditure line function number employee yearend employee benefit consist mainly life insurance scheme certain insurance scheme provide medical dental cover postemployment benefit employee cover retirement benefit plan sponsor group company nature plan vary accord legal regulation fiscal requirement economic con dition country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally united states plan usually fund payment group employee trust inde pendent ofthe group finances plan unfunded liability obligation record group balance sheet amount recognise arrive operate profit postemployment define benefit plan follow current service cost interest cost expect return plan asset net actuarial gain loss recognise past service cost gain loss curtailment total include employee remuneration gain curtailment million swiss franc relate reshape future growth programme include pharmaceutical division restructure restructuring cost income statement note actual return plan asset negative return million swiss franc posi tive return million swiss franc note consolidated financial statement movement net asset liability recognise balance sheet postemployment define benefit plan follow begin year change group organisation givaudan spinoff total expense include employee remuneration contribution pay benefit pay unfunded plan currency translation effect end year amount recognise balance sheet postemployment define benefit plan follow unfunded plan recognise liability actuarial present value unfunded obligation fund plan actuarial present value fund obligation past present employee plan asset hold trust fair value plan asset excess actuarial present value fund obligation unrecognised actuarial gain loss unrecognise past service cost net recognise asset liability fund obligation past present employee asset liability recognise deficit recognise liabilitie postemployment benefit surplus recognise longterm asset total net asset liability recognise amount include nonpension postemployment benefit scheme principally medical plan actuarial present value obligation million swiss franc million swiss franc plan asset million swiss franc million swiss franc therelate net liability recognise million swiss franc million swiss franc actuarial gain million swiss franc million swiss franc unrecognised amount recognise balance sheet postemployment define benefit plan predom inantly noncurrent report longterm asset noncurrent liability include fair value asset fund plan group nonvoting equity security fair value million swiss franc million swiss franc note consolidated financial statementsthe group operate define benefit scheme country actuarial assumption vary base local economic social condition range assumption theactuarial valuation significant define benefit plan country withstable currency interest rate follow discount rate project rate remuneration growth expect rate return plan asset healthcare cost trend rate group japanese subsidiary participate tokyo pharmaceutical welfare fund multi employer plan nature define benefit plan account define contribution plan financial statement group access sufficient information plan account define benefit plan contribution million swiss franc million swiss franc employee certain subsidiary group receive stock appreciation right sar compensation sar exercise vest period year cash payment base market price group american depositary share adss point exercise exceed strike price grant price issuance group accrue expect cash outflow outstanding sar december accrual require group operate option compensation plan certain employee group purchase option roche nonvoting equity security financial institution grant certain employee cost option defer deduction equity purchase expense grant employee obligation deliver nonvoting equity security rest financial institution operate income expense net millions chf royalty income gain disposal coreg operating income total operating income royalty expense ongoing restructure expense operate expense total operating expense total operating income expense net note consolidated financial statement financial income expense net millions chf gain sale marketable security loss sale marketable security gain sale labcorp share dividend income gain loss equity derivative net writedown impairment equity investment net income equity investment interest income gain loss interest rate derivative net writedown impairment longterm loan total interest income interest expense amortisation discount debt instrument time cost provision total interest expense foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss financial income expense net total financial income expense net gain loss derivative show follow implementation new international accounting standard financial instrument recognition measurement january note income taxis million chf income tax expense amount charge income statement follow current income taxis defer income taxis total charge income taxis group parent company roche holding ltd group operate company domicile switzerland maximum effective rate income taxis company domicile basel switzerland hold company operate company group operate world subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate increase operating income make considerably high pro portion pretax income case previous year lead increase group effective tax rate operating income typically occur jurisdiction high tax rate compare financial income note consolidate financial statementsthe group effective tax rate differ group expect tax rate follow group average expect tax rate tax effect income taxable expense deductible tax purpose difference gain sale genentech share gain sale labcorp share impairment longterm asset vitamin case group effective tax rate income tax asset liability amount recognise balance sheet income taxis follow current income taxis current income tax asset current income tax liability net current income tax asset liability balance sheet defer income taxis defer income tax asset defer income tax liability net defer income tax asset liability balance sheet amount recognise balance sheet defer taxis report longterm asset noncurrent liability approximately respectively current deferred income tax asset recognise tax loss carry forwards extent realisation relate tax benefit probable group significant unrecognised tax loss defer income tax liability establish withholding tax othertaxe payable unremitted earning certain foreign subsidiary assuch amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc defer income tax asset liability defer income tax charge credit attributable follow item property plant equipment restructure temporary intangible asset provision difference total net defer income tax asset liability begin year change accounting policy issue debt instrument charge credit income statement charge credit equity change group organisation currency translation effect net defer income tax asset liability end year note consolidated financial statement property plant equipment restructure temporary intangible asset provision difference total net defer income tax asset liability begin year change accounting policy issue debt instrument charge credit income statement change group organisation include givaudan spinoff currency translation effect net defer income tax asset liability end year property plant equipment million chf building land machinery improve construction land ment equipment progress total total net book value beginning year currency translation effect change group organisation include givaudan spinoff genentech synthetic lease addition disposal transfer depreciation charge pharmaceutical division restructuring impairment charge impairment charge end year december cost accumulate depreciation net book value group subsidiary genentech synthetic lease certain facility california innovember genentech enter transaction refinance large synthetic lease special purpose entity structure group accounting policy beconsolidate accordingly property plant equipment site net book value million swiss franc record group balance sheet additional million swiss franc record shortterm debt addition group consider appro priate record remain genentech synthetic lease finance lease accordingly hasrecorde additional million swiss franc property plant equipment longterm finance lease payable reclassification record effective january group operating income include year depreciation charge facility effect reclassifica tion reduce net income million swiss franc equivalent million swiss franc note consolidated financial statementsexclude genentech synthetic lease december capitalise cost machinery equipment finance lease amount million swiss franc million swissfranc net book value asset amount million swiss franc million swiss franc operating lease commitment december future minimum annual payment noncancellable operating lease follow year year total minimum annual payment total rental expense operating lease million swiss franc mil lion swiss francs group capital commitment purchase construction property plant equipment total billion swiss franc intangible asset millions chf patent licence trademark goodwill total total net book value beginning year change accounting policy currency translation effect change group organisation include givaudan spinoff addition disposal amortisation charge impairment charge end year december cost accumulate depreciation end year january group recognise impairment charge million swiss franc implement change accounting policy note charge million swiss franc credit million swiss franc recognise base change recoverable amount impair asset year note consolidated financial statement investment associate company joint venturesin millions chf group investment associate company list account equity method share net income balance sheet value laboratory corporation america holdings usa basilea pharmaceutica switzerland investment account equity method total investment account equity method laboratory corporation america holdings june group sell share labcorp result pretax gain incidental cost million swiss franc record financial income expense net net pretax cash inflow million swiss franc date sale group remain investment labcorp account availableforsale mar ketable securities june labcorp announce call redemption july outstanding convertible preferred stock redemption period group sell suffi cient hold labcorp ordinary stock group noncontrolle interest labcorp similar level redemption date group realise pretax gain million swiss franc process october group sell share labcorp result pretax gain incidental cost million swiss franc transaction result net pretax cash inflow million swiss franc basilea pharmaceutica october group contribute cash million swiss franc establish newly form swiss company basilea pharmaceutica ltd basilea group transfer certain knowhow intellectual property antibiotic antifungal dermatology property plant equipment basilea consideration million swiss franc october group sell share basilea group retain noncontrolle interest basilea transaction group associate company follow income statement income sale good supply service expense purchase good supply service balance sheet trade account receivable note consolidated financial statementsbayer joint venture group stake bayer roche llc joint venture bayer group overthecounter otc field market distribute product aleve otc product united states joint venture include financial statement theproportionate consolidation method effect income statement balance sheet isas follow income statement sale expense net income taxis balance sheet longterm asset current asset noncurrent liabilitie current liability net asset investment millions chf noncurrent investment availableforsale investment heldtomaturity investment total investment investment hold strategic purpose classified noncurrent marketable security hold fund management purpose classify current note follow change accounting policy note availableforsale investment carry fair value availableforsale investment value low cost market value fair value availableforsale investment december mil lion swiss franc million swiss franc report carry value heldtomaturity investment hold amortise cost effective interest rate longterm asset millions chf recognise surplus fund pension plan loan receivable prepay employee benefit restrict cash total longterm asset loan receivable comprise loan party term year record amortise cost restrict cash consist cash set aside collateral certain lease agreement longterm asset consist asset show sepa rately group expect derive economic benefit year note consolidated financial statement inventory million chf raw material supply work process finish good provision slowmove obsolete inventory total inventory inventory hold net realisable value carry value million swiss franc million swiss franc account receivable trade millions chf account receivable note receivable provision doubtful account total account receivable trade december account receivable trade include amount denominate dollar equivalent billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc bad debt expense million swiss franc million swiss franc current assetsin millions chf accrue interest income prepaid expense derivative financial instrument receivables total current asset marketable securitiesin million chf availableforsale current investment share bond debenture money market instrument total marketable security marketable security hold fund management purpose classified ascurrent investment hold strategic purpose classify noncurrent note follow change accounting policy note marketable security carry atfair value marketable security value low cost market value fair value marketable security december million swiss franc million swiss franc report carry value share consist primarily readily saleable equity security note consolidated financial statementsbond debenture contract maturity average effective interest rate year year year year year year money market instrument generally fix interest rate range depend currency denominate contract mature year december accrue current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability equity share capital annual general meeting april shareholders approve stock split share nonvoting equity security roche holding ltd split take place number share nonvoting equity security issue respectively nominal value share swiss franc nonvoting equity security nominal value comparative share information restate split base information supply roche shareholder group pool voting right comprise hoffmann michalskihoffmann hoffmann hoffmann msv oerihoffmann oeri duschmaloeri oeri oeri oeri gerber group hold share share split precede year figure include share pooled voting right hold outside group individual member group transaction individual ordinary course business note consolidated financial statement nonvoting equity security genussscheine december nonvoting equity security issue swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company isentitle times exchange nonvoting equity security share participation certificate dividend april shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc record retain earning shareholder approve special dividend respect givaudan spinoff account ing effect distribution primarily include carry value group financial statement asset liability givaudan total million swiss franc include special dividend movement retain earning equity instrument december number nonvoting equity security hold net cash inflow transaction equity instrument million swiss franc net cash outflow million swiss franc group hold equity instrument primarily meet obligation arise respect certain group debt instrument achieve hold physical nonvoting equity security hold derivative instrument forward contract option december group hold derivative instrument equivalent nonvoting equity security instrument exercise total nonvoting equity security available group reduction number nonvoting equity security physically hold group increase total number share outstanding figure earning share calcula tion impact reduce earning share earning share nonvoting equity security share information restate share split take place note basic earning share nonvoting equity security net income millions chf number share million number nonvoting equity security millions weight average number nonvoting equity security hold million total million basic earning share nonvoting equity security chf note consolidated financial statementsdilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security weight average number share nonvoting equity securities outstanding adjust assume conversion dilutive potential share nonvoting equity security net income millions chf elimination interest expense net tax convertible debt instrument dilutive millions chf increase minority share group net income net tax assume outstanding genentech stock option exercise net income calculate diluted earning share million chf weight average number share nonvoting equity security issue million adjustment assume conversion convertible debt instrument dilutive million weight average number share nonvoting equity security issue calculate dilutive earning share millions diluted earning share nonvoting equity security chf retain earningsin millions chf fair value fair value reserve reserve accumulate available qualifying equity currency profit forsale cash flow conversion translation loss investment hedge option reserve total total beginning year change accounting policy net income dividend pay givaudan spinoff special dividend transfer net asset change fair value recognise net income defer income taxis minority interest equity component new convertible debt currency translation gain loss total note consolidated financial statement minority interestsin millions chf beginning year change accounting policy givaudan spinoff sale genentech share conversion option embed lyon note issue minority share group net income net tax net effect movement fair value charge credit equity net effect exercise genentech stock option genentech stock repurchase currency translation effect end year genentech total minority interest genentech december minority interest genentech publicly hold party group transaction genentech share describe note december genentech option outstanding employee stock option plan entitle holder exercise option purchase million share price range usd usd option outstanding million exercisable date debtin million chf amount bank financial institution debt instrument capitalise lease obligation borrowing total debt current portion longterm debt amount year total longterm debt shortterm debt total million swiss franc million swiss franc consist current portion longterm debt show table shortterm bank loan overdraft shortterm debt amount million swiss franc million swiss franc balance include million swiss franc shortterm debt million swiss franc longterm finance lease payable respect genentech synthetic lease note note consolidated financial statementsrepayment term longterm debt year year year year year total longterm debt lyon zero coupon dollar exchangeable note reflect year holder note request group purchase note fair value longterm debt billion swiss franc billion swiss franc iscalculate base present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period amount bank financial institution interest rate amounts primarily denominate dollar euro average approximately repayment date vary year debt instrument carry value group debt instrument give table effective interest rate swiss franc bond bullet principal billion swiss franc rodeo principal billion swiss franc dollar bond bull spread principal billion dollar chameleon principal billion dollar japanese yen bond samurai principal billion japanese yen swiss franc convertible bond helveticus dividendlinke convertible bond principal billion swiss franc zero coupon dollar exchangeable note lyon principal billion dollar lyon iii principal billion dollar lyon principal billion dollar lyon principal billion dollar japanese yen exchangeable bond sumo principal billion japanese yen limited conversion prefer stock total debt instrument note consolidated financial statement repayment bull spread dollar bond date group repay principal billion dollars ofthe dollar bond originally issue result cash outflow mil lion swiss franc issue lyon dollar note exchangeable nonvoting equity securities july group issue zero coupon dollar exchangeable note july principal million dollar note exchangeable nonvoting equity security time prior maturity net proceed issue million dollar million swiss franc initially allocate million swiss franc debt million swiss franc unamor tise discount million swiss franc equity respect conversion option embed bond million swiss franc defer tax liability swiss franc convertible bond helveticus annual payment distribution pay july bond chf par value place fix rate interest annual payment distribution equal time ordinary andor extraordinary dividend declare nonvoting equity security roche holding ltd business year end december nineteen month prior july relevant year bond exchangeable non vote equity security roche hold ltd time life bond accordance term bond additional cash payment chf conversion ofeach bond zero coupon dollar exchangeable note lyons note exchangeable american depositary share adss adjust exchange ratio exchange adss usd principal maturity note group purchase note cash option holder april purchase price usd principal note usd addition note redeemable option group time april issue price plus accrue original issue discount oid lyon iii note exchangeable adss exchange ratio exchange adssper usd principal maturity note group purchase note cash option holder purchase price usd principal note usd usd respectively addition note redeemable option group time issue price plus accrue original issue discount oid lyon note exchangeable genentech share exchange ratio genentech share usd principal maturity note group right pay cash equal market value genentech share lieu deliver genen tech share group purchase note cash option holder january january purchase price usd principal note usd usd respectively addition note redeemable option group time january issue price plus accrue original issue discount oid note consolidated financial statementslyon note exchangeable adss exchange ratio exchange adssper usd principal maturity note group purchase note cash option holder january july july purchase price usd principal note usd usd usd respectively addition note redeemable option group inwhole time july issue price plus accrue original issue discount oid japanese yen exchangeable bond sumo bond jpy par value exchangeable nonvoting equity security roche holding ltd exchange ratio bond redeemable maturity issue price plus accrue original issue discount oid unamortised discount include carry value debt instrument follow unamortised discount swiss franc bond dollar bond japanese yen bond swiss franc convertible bond zero coupon dollar exchangeable note japanese yen exchangeable bond total unamortised discount derivative financial instrument millions chf appropriate circumstance group use derivative financial instrument risk management trading strategy discuss note follow change accounting policy derivative financial instrument carry fair value change accounting policy method determine fair value describe note fair value derivative financial instrument december million swiss franc million swiss franc report carry value foreign currency derivative forward exchange contract swap option interest rate derivative swap derivative total carrying value derivative financial instrument asset liability recognise current asset accrue current liability total net asset liability recognise note consolidated financial statement hedge accounting follow implementation new international accounting standard financial instrument recognition measurement group change policy hedge account e effective january new policy describe note require toqualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy cover foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropri eat certain risk alter use derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instru ment hedged item report independently hedge relationship mean derivative report fair value change fair value include financial income expense considerable administrative cost maintain necessary documentation tracking procedure group generally limit use hedge account certain signifi transaction consequently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe fair value hedge group equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure group enter derivative financial instrument zero cost collar forward contract change fair value report financial income expense cash flow hedge group expect foreign currency cash flow future royalty income development expense hedge transaction exposure group enter derivative financial instrument option forward contract group anticipate cash flow interestbeare investment expose change interest rate manage risk group enter interest rate swap agreement effectively convert expect interest income variable fix rate ment fair value reserve designate cash flow hedge disclose note note consolidated financial statement provision million chf restructure provision provision total total beginning year change group organisation include givaudan spinoff pharmaceutical division restructure additional provision create amount utilise year additional provision create respect vitamin case provision additional provision create unused amount reverse utilise year increase discount passage time change discount rate currency translation effect end year current portion provision noncurrent portion provision total provision restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provi sion include cost necessarily entail restructuring associate ongoing activity group creation provision record charge operating income arise restructure newly acquiredcompanie case include acquisition accounting form goodwill note pharmaceutical division restructure provision consist mainly legal environmental similar matter provision include provision respect vitamin case note contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group engage subject physical risk kind nature frequency development event cover insurance effect future operation earning predictable note consolidate financial statement vitamin case provision record respect vitamin case disclose note provi sion group good current estimate total liability arise assessment base currently available information litigation process new litigation arise possible final obligation different igen litigation february united states district court maryland enter judgement civil litigation roche diagnostic gmbh germany rdg igen international inc igen claim relate licensing igen electrochemiluminescence ecl rdg court conclude breach licence agreement material igen right terminate licence agreement award igen million dollar compensatory damage million dollar punitive damage rdg file appeal decision exist order court bar licence termination appeal proceeding complete appeal progress rdg continue provide customer product service continue plan innovation base ecl technology rdg previously boehringer mannheim litigation matter acquire boehringer mannheim rdg assess igen litigation adequacy provision record boehringer mannheim rdg reassess adequacy provision conclude base currently available information appropriate record additional provision point total provision liability thatrdg expect pay adjust foreign currency translation effect time value money litigation process possible final obligation different total provision disclose prejudice rdg position current litigation provision significantly amount award court cash flow statementin million chf cash flow operating activity cash flow operating activity derive group primary activity asdescribe divisional review calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show cash flow statement operate cash flow include income taxis pay activity include example taxis pay gain genentech labcorp share sale note consolidated financial statement net income add nonoperate income expense financial income expense net income taxis change accounting policy income applicable minority interest share result associate company operate profit depreciation property plant equipment amortisation intangible asset impairment longterm asset gain sale genentech share charge vitamin case charge pharmaceutical division restructure genentech inventory writeup charge expense define benefit postemployment plan adjustments cash generate operation cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity proceed issue longterm debt lyon zero coupon exchangeable dollar note lyon zero coupon exchangeable dollar note sumo exchangeable japanese yen bond longterm bank loan borrowing total repayment longterm debt repayment bull spread dollar bond repayment knock dollar bond exercise helveticus dividendlinke swiss franc convertible bond longterm bank loan borrowing total interest dividend pay interest pay dividend pay total note consolidated financial statement cash flow invest activity cash flow invest activity principally arise group investment inproperty plant equipment intangible asset acquisition divestment subsidiary associate company business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect change group organisation cash generate group investment cash flow marketable security include income capital gain loss show net movement group portfolio consist large number position hold longterm basis acquisition subsidiary associate company product amira cash contribution basilea acquisition total divestment subsidiary associate company product proceed sale genentech share proceed sale labcorp share divestment total interest dividend receive interest receive dividend receive total subsequent event vitamin fine chemical division management begin evaluation strategic option respect vitamin andfine chemical division date approval financial statement board director approve detailed formal plan announcement intention madeaccordingly vitamin fine chemical division remain classified continuingoperation financial statement sale labcorp share february labcorp file registration statement announce group plan offer sale million share labcorp option sell million share cover overallotment assume total million share sold roche ownership interest labcorp reduce approximately approxi mately note consolidated financial statementsreport group auditor general meeting roche holding ltd basel auditor group audit consolidated financial statement roche group page year end december consolidated financial statement responsibility board director roche holding ltd responsibility express opinion consolidated financial statement base audit confirm meet swiss legal requirement con cerne professional qualification independence audit conduct accordance auditing standard promulgate swiss pro fession international standard auditing issue international federation accountant require audit plan perform obtain reasonable assurance consolidated financial statement free material misstate ment examine test basis evidence support amount disclosure theconsolidate financial statement assess accounting principle significant estimate overall consolidated financial statement presentation webelieve audit provide reasonable basis opinion opinion consolidate financial statement roche group present fairly material respect financial position december result operation cash flow year end accordance international accounting standard comply swiss law recommend consolidated financial statement submit approve pricewaterhousecoopers william kirst richard tgwinter basel february report group auditor multiyear overview statistic report statement income millions chf sale ebitda operating profit net income research development balance sheet million chf longterm asset current asset total asset equity minority interest noncurrent liability current liability addition property plant equipment personnel number employee end year key ratio net income sale net income equity research development sale current ratio equity minority interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf cash warrant addition dividend adjust chf cash warrant addition dividend unadjuste chf information table state report change accounting policy arising change international accounting standard stock split arenot apply retrospectively warrant hold final exercise date addition normal dividend shareholder approve share nonvoting equity security special centenary warrant worth chf date issue holder option cash equivalent chf net income relate key ratio show special charge million swiss franc net tax incur follow corange acquisition include corange respect balance sheet datum multiyear overview warrant hold final exercise date dividend include special dividend relate spinoff fragrance flavour division dividend propose board director multiyear overview sale division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour total sale geographical area millions chf switzerland european union rest europe europe north america latin america asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour total addition property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america asia africa australia oceania total multiyear overviewholde finance company boehringer mannheim far east pte ltd singapore corange deutschland hold gmbh mannheim germany corange ltd hamilton bermuda hoffmannla roche france sas neuillysurseine france roche capital corporation panama city panama roche capital market international limited peter port guernsey roche capital transactions limited hamilton bermuda roche china limited shanghai china roche deutschland hold gmbh grenzachwyhlen germany roche financial management inc panama city panama roche financial product limited hamilton bermuda roche finanz basel switzerland roche hold limited welwyn garden city great britain roche holdings inc wilmington delaware usa roche international finance bermuda ltd hamilton bermuda roche international finance corporation limited peter port guernsey roche international ltd hamilton bermuda roche kapitalmarkt basel switzerland roche pharmholde mijdrecht netherland roche treasury management europe ltd basel switzerland roche vitamin hold basel switzerland sapac corporation ltd montevideo uruguay syntex corporation panama city panama company wholly own group hold finance company roche security share price performance chf roche share adjust swiss market index rebase nonvoting equity security genussschein price performance chf roche nonvoting equity security adjust swiss market index rebase american depositary receipt adr price performance usd roche adr adjust index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july roche securitiesnumber share nonvoting equity securitiesa number share nominal value chf chf number nonvoting equity security genussscheineno nominal value total datum share nonvoting equity securityc chf net income equity dividend stock price shareb high low yearend stock price nonvoting high equity security low genussscheinb yearend historic stock price unadjusted share yearend nonvoting equity security genussschein yearend market capitalisation unadjuste millions chf yearend key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share unadjuste priceearning nonvoting equity security genussscheine unadjuste nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price stock price figure prior june adjust effect givaudan spinoff adjustment factor share nonvoting equity security factor independent financial institution net income share prior market capitalisation figure assume equity instrument hold outstanding net income relate key ratio show special charge million swiss franc net tax incur follow corange acquisition include corange respect balance sheet datum dividend include special dividend relate spinoff fragrance flavour division dividend propose board director ticker symbol share nonvoting american equity security depositary receipt reuter roczs roczgs rohhypk bloomberg rog rohhy swx swiss exchange rog roche security outstanding bond summarise bond term exchange term warrant samurai warrant exercise june holder face value jpy billion warrant receive chf cash coupon issuer roche financial management inc roche holding ltd attach warrant relate roche nonvoting equity security genussscheine lyon april note exchangeable american depositary share face value usd adss adjust exchange ratio exchange coupon zero adss usd principal maturity note issuer roche holdings inc exchange ratio change accordance inden roche hold ltd ture agreement date april effective date exchange right roche adss group purchase note cash option holder april purchase price perusd principal note usd inaddition note redeemable option group time april issue price plus accrue original issue discount oid helveticus july bond chf par value exchangeable non face value chf voting equity security roche hold ltd time coupon times ordinary andor life bond accordance term bond extraordinary dividend nonvoting additional cash payment chf conver equity security genussscheine sion bond chf par value issuer roche capital market international limited roche holding ltd conversion right roche nonvoting equity security lyon note exchangeable american depositary share face value usd adss exchange ratio exchange adss coupon zero usd principal maturity note issuer roche holdings inc exchange ratio change accordance indenture roche holding ltd agreement date effective date exchange right roche adss group purchase note cash optionof holder pur chase price usd principal note usd usd respectively addition note willbe redeemable option group atany time issue price plus accrue original issue discount oid roche securitiesoutstanding bond summarise bond term exchange term warrant rodeo march warrant expire unexercised march face value chf coupon issuer roche kapitalmarkt roche holding ltd attach warrant roche nonvoting equity security genussscheine bullet march face value chf coupon issuer roche international finance corporation limit roche holding ltd chameleon july face value usd coupon issuer roche holdings inc roche holding ltd lyons january note exchangeable genentech share face value usd exchange ratio genentech share usd coupon zero principal maturity note group issuer roche holdings inc theright pay cash equal market value genen roche hold ltd tech share lieu deliver genentech share group exchange right purchase note cash option holder genentech common stock january january purchase price usd principal note usd andusd respectively addition note redeemable option group anytime january issue price plus accrue original issue discount oid sumo march bond jpy par value exchangeable face value jpy nonvoting equity security roche holding ltd coupon exchange ratio bond redeemable issuer roche holdings inc maturity attheissue price plus accrue original issue roche holding ltd discount oid exchange right roche nonvoting equity security genussscheine accordance term bond exchange ratio adjust june roche security outstanding bond summarise bond term exchange term warrant lyon july note exchangeable american depositary share face value usd adss exchange ratio exchange adss coupon zero usd principal maturity note group issuer roche holdings inc purchase note cash option holder roche holding ltd january july july purchase exchange right roche adss price usd principal note usd usd usd respectively addition note redeemable option group time july issue price plus accrue original issue discount oid roche securitiesroche holding ltd basel financial statement income statement millions chf income income participation interest income loan group company interest investment income income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year financial statement balance sheet december millions chf longterm asset participation loan group company total longterm asset current asset account receivable group company account receivable prepay expense accrue income marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company liabilitie accrue liability total current liability total liability total equity liability pro memoria nonvoting equity security nominal value financial statementsnote financial statement general financial statement roche holding ltd basel prepare accordance provision swiss company law accept business principle valuation method translation foreign currency balance sheet asset liability disclose net realisable value exception tothis rule participation show acquisition value appropriate writedown marketable security show low cost market value unrealise foreign currency gain balance sheet item defer expense income aswell foreign currency transaction translate exchange rate rule relevant transaction date detail specific item income total income million swiss franc million swiss franc higher previous year mainly improved operating income taxis tax charge include corporate income capital taxis withhold taxis stamp duty equity total equity equal total asset share capital previous year share capital amount million swiss franc annual general meeting decide april split bearer share non voting equity securitiesfrom split take place share capital consist bearer share nominal value chf nonvoting equity securitiesgenussscheine nominal value guarantee guarantee favour group company total million swiss franc previous year million swiss franc time prepare balance sheet risk arise contingent liability discernible pledge asset asset total book value million swiss franc previous year pledge security company commitment note financial statement participation major participation list page important shareholder share company issue bearer reason company notkeep register shareholder follow figure base information share holder shareholder validation check annual general meeting april onother information available company previous year stock split share shareholder groupwith pool voting right comprise hoffmann michalskihoffmann msmahoffmann hoffmann msv oerihoffmann oeri duschmaloeri oeri oeri oeri anddr gerbera share novartis basel include affiliate thereofb information supply shareholder december figure share include share pooled voting right hold outside group individual member group figure december supply novartis international ltd basel notes financial statementsappropriation available earning proposal general meeting chf available earning net profit year balance bring forward previous year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf stock split year transfer free reserve total appropriation available earning carry forward account appropriation available earning report statutory auditor general meeting roche holding ltd basel statutory auditor audit accounting record financial statement income statement balance sheet note page roche holding ltd basel forthe year end december financial statement responsibility board director responsibility toexpress opinion financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance auditing standard promulgate swiss profession require audit plan perform manner obtain reasonable assurance financial statement free material misstatement examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate overall financial statement presentation believe audit provide reasonable basis opinion opinion accounting record financial statement propose appropriation available earning comply swiss law company article incorporation recommend financial statement submit approve ernst young ltd conrad lffel jrg zrcher basel february report statutory auditor arctic circle tropic cancer tropic capricorn roche rcrc letic global market presence sale switzerland manufacture argentina research development australia toe mic rii party austria bangladesh belgium bermuda brazil canada chile china colombia costa rica czech republic denmark dominican republic ecuador egypt salvador finland france germany great britain greece guatemala roche global market presence arctic circle tropic cancer tropic capricorn cnt rcrc letic honduras south korea hungary spain india sweden indonesia taiwan ireland thailand israel turkey italy uruguay japan usa malaysia venezuela mexico vietnam morocco netherlands new zealand nicaragua norway pakistan panama peru philippine poland portugal puerto rico russia singapore south africa roche global market presence operating subsidiary associate company group hold interest switzerlandf hoffmannla roche ltd roche diagnostic hong kong limit mostofthe company list exception basel roche ltd sisseln teranol ltd hong kong colombia producto roche aremarke single dot lalden roche pharma switzerland bogot roche vitaminas colom group interest ltd reinach roche diagnostic bia bogot costa rica producto double dot group interest schweiz ltd rotkreuz roche diag roche interamericana san jos nostics international ltd cham roche roche servicios san jos roche vitamin europe ltd birsfelden roche costa rica san jos roche vita december instrument center ltd rotkreuz roche minas costa rica san jos czech consumer health ltd kaiseraugst republic roche sro prague denmark include change group membership roche vitamin ltd basel basilea roche hvidovre roche vitamin february pharmaceutica ltd basel argentina hvidovre dominican republic pro producto roche qumica indus ducto rochedominicana santo trial buenos air roche vitaminas domingo roche vitaminas domini argentina buenos air australia cana santo domingo ecuador roche product pty limited dee roche ecuador quito egypt roche vitamin australia pty limited rovigypt ltd giza roche egypt ltd french forest syntex australia limited giza salvador productosroche north sydney roche diagnostic aus elsalvador san salvador tralia pty limited castle hill austria finlandroche espoo france roche austria gmbh vienna roche hoffmannlaroche france sas diagnostic gmbh vienna bangladesh neuillysurseine produit roche roche bangladesh ltd dhaka neuillysurseine roche diagnostic belgiumnv roche brussels meylan roche vitamine france sacitrique belge tienen roche villageneuf laboratoire roche vitamin deinzeastene roche nicholas gaillard germany roche diagnostic belgium brussels deutschland holding gmbh grenzach bermuda syntex pharmaceutical wyhlen corange deutschland hold international limited hamilton brazil gmbh mannheim consulab mannheim produto roche qumico farmacuti gmbh mannheim pharma waldhof cos paulo avl ltda gmbh mannheim hoffmann paulo roche vitaminas brasil ltda roche aktiengesellschaft grenzach paulo canadahoffmannla roche wyhlen roche consumer health limited toronto roche vitamins deutschland gmbh eppstein roche canada inc cambridge ontario chile diagnostics gmbh mannheim galenus producto roche ltda santiago mannheim gmbh mannheim hestia chile roche vitaminas chile pharma gmbh mannheim roche vita puerto montt china roche shanghai gmbh grenzachwyhlen great fine chemicals ltd shanghai roche britain roche product limited welwyn china limited shanghai shanghai garden city roche diagnostic ltd roche pharmaceuticals limited shang lewe roche vitamin ltd hai roche shanghai vitamins ltd welwyn garden city roche registration shanghai roche zhongya wuxi limited welwyn garden city greece citric acid ltd wuxi roche diagnos roche hellas athens roche tic shanghai limited shanghai vitamin hellas epe athens roche roche hong kong limited hong kong vitamin international marketing centre operating subsidiary associate companiesepe athens guatemala producto productos roche panam panama uruguay montevideo usa roche roche guatemala guatemala city roche vitaminas interamrica holdings inc wilmington delaware honduras producto roche honduras panama city peru productos hoffmannlaroche inc nutley new tegucigalpa hungary roche roche qumica farmacutica lima jersey roche laboratories inc nutley hungary ltd budap roche vitamin philippine roche philippines inc new jersey roche vitamins inc hungary ltd ujhartyan india roche makati roche vitamin philippine parsippany new jersey roche scientific company india private inc manila poland roche polska molecular systems inc pleasanton limit mumbai indonesia roche spzoo warsaw roche diagnostic california american roche interna indonesia jakarta ireland roche polska warsaw roche tional inc little fall new jersey products ireland limited dublin witaminy polska zoo mszczonw roche carolina inc florence south roche ireland limited clarecastle portugal roche farmacutica qumica carolina genentech inc south san israel roche pharmaceuticals israel lda amadora roche sistemas francisco california syntex usa ltd telaviv italy roche spa milan diagnsticos sociedade unipessoal llc palo alto california roche roche diagnostic spa milan istituto lda lindaavelha puerto rico syntex colorado corporation boulder delle vitamine spa milan japan puerto rico inc humacao russia colorado bayerroche llc nippon roche tokyo nutritec roche moscow ltd moscow singa morristown new jersey roche ltd tokyo roche diagnostic pore roche singapore pte ltd singa diagnostic corporation indianapoli tokyo roche vitamin japan pore roche diagnostic asia pacific indiana venezuela productos roche tokyo malaysia roche malaysia sdn pte ltd singapore roche vitamin caracas roche vitaminas bhd kuala lumpur roche diagnostic asia pacific pte ltd singapore south venezuela victoriavietnam malaysia sdn bhd kuala lumpur africa roche product proprietary roche vitamin vietnam limited roche vitamin malaysia sdn bhd limited johannesburg south korea binhduong province kuala lumpur mexico productos roche korea company ltd seoul roche mexico city syntex roche diagnostic korea ltd mexico city grupo roche seoul roche vitamin korea ltd syntex mxico mexico seoul spain roche farma madrid city lakeside mxico march roche vitaminas mexico city roche vitaminas mxico madrid andreu roche salto jalisco morocco madrid syntex roche madrid roche casablanca roche immo roche diagnostic barcelona bilire maroc sarl casablanca boehringer mannheim roche thenetherland roche pharmholde madrid sweden roche stockholm mijdrecht roche nederland roche diagnostic scandinavia mijdrecht roche diagnostic neder bromma taiwan roche products ltd land almere roche vitamin taipei roche diagnostics ltd taipei venlo new zealand roche product roche vitamin taiwan limited taipei new zealand limited auckland thailand roche thailand limited roche vitamin new zealand limited bangkok rovithai limited bangkok auckland roche diagnostic new roche diagnostic thailand limited zealand pty ltd auckland nicaragua bangkok turkey roche mstahzarlar producto roche nicaragua sanayi anonim sirketi istanbul roche managua norway roche norge diagnostik sistemleri ticaret oslo pakistan roche pakistan ltd istanbul uruguay roche international karachi panama productos roche ltd montevideo sapac corporation interamericana panama city ltd montevideo roche vitaminas operating subsidiary associate company cautionary statement forwardlooke statement annual report contain certain forward opment economic condition delay look statement forwardlooke inability obtain regulatory approval bring statement identify byword ing product market fluctuation currency believe expect anticipate project intend exchange rate general financial market seek estimate future similar condition uncertainty discovery devel expression discussion opment market new product new use thing strategy goal plan intention exist product increase government factor cause actual result differ materially price pressure interruption production future reflect forwardlook loss inability obtain adequate protection ing statement contain annual report intellectual property right litigation price product initiative loss key executive orother employee ofcompetitor legislative regulatory devel adverse publicity news coverage publish hoffmannla roche ltd basel switzerland tel fax medium office corporate communication basel switzerland tel fax investor relations basel switzerland tel fax world wide web httpwwwrochecom order tel fax publication email baselwebmasterrochecom annual general meeting april trademark mention enjoy legal protection roche annual report publish german original language english roche annual report issue hoffmannla roche ltd basel corporate communication design wirz identity zurich photo tina steinauer zurich roche corporate photolibrary basel typeset staufferfebel basel lithos lithoteam allschwilbasel printer birkhusergbc reinachbasel bind buchbinderei grollimund reinachbasel cover influenza virus transmission electron microscopyvitamin fine chemical diagnostic sale division pharmaceutical latin america asia sales region europe north america vitamin fine chemical diagnostic employee division pharmaceutical latin america asia employees region north america europe